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Abstract 
 
Cardiac autonomic neuropathy (CAN) is a disease caused by a complication of diabetes and 
is known as a silent killer. CAN causes irregular blood pressure and abnormal heart rate as well 
as increased risk of cardiac-related morbidity and mortality of diabetes patients. Diabetic 
neuropathy can also cause kidney failure, urinary dysfunction and cardiac arrhythmias since 
diabetic neuropathy can impair the proper functioning of the major organs. It is imperative to 
detect CAN early to prevent complications, reversing or decreasing progression and administer 
timely and appropriate treatment to reduce CAN-borne morbidity and mortality of diabetics. 
However, because it is difficult to conduct the current tests, which are not sensitive enough, 
CAN often remains mostly undetected.  
The objectives of this thesis were three-fold: The first aim was to investigate the roles of 
various markers in the prevalence and complications of CAN and associated diseases with 
emphasis on diabetes mellitus. Specifically, this study investigated the role of heart rate 
variability (HRV) markers as well as the roles of genetic and family history risk factors. The 
second aim of this study was to develop mechanisms to predict CAN disease occurrence. The 
third aim of this current study was to develop a model for predicting diabetes mellitus (DM) 
and cardiovascular disease (CVD) simultaneously using common risk factors. 
Although research in automating and improving the early detection of CAN has recently 
received serious attention, identifying clinical variables such as genetic risk factors and family 
history to determine their capabilities as predictors of the disease prevalence remains an open 
problem. First, this study examined the roles of genetic risk factors in the prevalence of CAN 
disease. To address this problem, a cross-sectional study was used to investigate the relationship 
between angiotensin-converting enzyme gene (ACE) polymorphism and CAN. Second, family 
history is an important non-modifiable risk factor for various pathologies such as diabetes 
mellitus (DM). In order to explore the effects of family history on developing diabetes mellitus 
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(DM), this study used a cross-sectional study to investigate the role of family history as a 
predictor of incident of diabetes mellitus in the rural community of Australia. The findings of 
this current study indicated family history was significantly related to the prevalence of the 
disease. This study also explored Ewing Battery Test (EBT) capability in diagnosing diabetes 
mellitus disease.  
EBT is the most widely used CAN assessment method in clinical practice. It is the common 
noninvasive approach for diagnosing CAN. EBT constitutes a set of tests that measure the 
response of heart rate (HR) and blood pressure (BP) during diverse activities and positions of 
the patients. Unfortunately, the standard EBT suffers from a number of shortcomings. 
However, it is quite common that sometimes-key information is missing due to the fact that 
not it is not always possible to apply the full five Ewing tests. This study investigated the role 
of HRV markers in enhancing the predictive accuracy of the diagnosis of CAN progression, 
particularly since there is no complete set of EBT. For the purpose of addressing this issue, a 
predictive model was developed that combines EBT with HRV markers to enhance the 
diagnosis of CAN. 
Timely recognition of CAN will help facilitate immediate and sufficient care for the patients 
to limit further deterioration of nerve damage, which stresses the need for early diagnosis of 
CAN. Although there have been several CAN predictive models proposed, they all focus on 
predicting the disease label such as normal, early, definitive, severe or atypical. These studies 
do not indicate the likelihood of a particular patient developing the disease. To address this 
problem, this current study proposed a predictive model that uses logistic regression method. 
The proposed predictive model has prediction accuracy rate of 87.31%, sensitivity 87.12%, and 
specificity 87.5%. The predictive model has furthermore confirmed the predictability of 
Ewing’s Tests with Normal and Early categories of CAN’s disease. Such a model can help both 
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patients and doctors to understand the progression of the disease and provides the appropriate 
and timely intervention.  
Moreover, CAN is a severe complication of diabetes mellitus (DM), which has a strong 
association with heightened risk of cardiovascular diseases (CVD). This explains why diabetes 
mellitus patients are at high risk of cardiovascular diseases. The increasing recognition of 
diabetes mellitus as a major cardiovascular disease risk factor has motivated greatly increased 
research on cardiovascular complications of diabetes. In this regard, an important research 
question is how to predict diabetes mellitus and cardiovascular disease simultaneously. This is 
a significant problem as the public health effect of cardiovascular disease on patients with 
diabetes is currently enormous and continues to increase. To solve this problem, this study 
developed a multi-diseases prediction model that enables physicians to predict diabetes 
mellitus and cardiovascular disease simultaneously based on their common risk factors.  
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Chapter 1: Introduction 
1.1  Background  
Cardiac Autonomic Neuropathy (CAN) is a disease of microvascular diabetes’ complications. 
It is linked with damage to the autonomic nervous system innervating the heart and connected 
to an increased risk of arrhythmia and sudden cardiac death, especially in diabetes mellitus type 
1 and type 2 [1-3]. It is well known that CAN is an early and frequent complication of diabetes 
mellitus (DM) with a significant source of morbidity and mortality in DM patients [4]. It affects 
seven to 15% of newly-diagnosed DM patients with 90% of those in line for a double transplant 
[5]. Although CAN shows high prevalence in diabetes patients, it is diagnosed less frequently 
and subsequently less undertreated diabetic chronic complication [6]. 
Diabetic neuropathy can impair the proper functioning of the major organs and it can 
eventually lead to serious life-threating health problems such as kidney failure, urinary 
dysfunction, and cardiac arrhythmias. In light of these consequences of diabetic neuropathy, it 
is imperative to identify CAN early. An early identification of CAN will help prevent possible 
complications, reversing or decreasing progression. It also helps to administer timely and 
appropriate treatment to reduce CAN-borne morbidity and mortality of diabetes patients. In 
addition, early diagnosis of CAN is necessary to provide sufficient care for CAN patients as 
well as to control further deterioration of nerve damage.  
One way to be able to identify CAN early is to develop a predictive approach that is capable 
of predicting the likelihood of a particular patient developing the disease and its progression. 
Such a model can help both patients and doctors to understand the progression of the disease 
and provide the appropriate and timely intervention. Existing predictive models for CAN 
generally concentrate only on predicting the disease label such as normal, early, definitive, 
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severe or atypical. Therefore, an approach that can inform the likelihood of a particular patient 
developing the disease and its progression is yet to be addressed.  
As CAN leads to an increased risk of sudden cardiac death, an early detection of CAN is 
paramount particularly in diabetic patients [7]. Various invasive and non-invasive tests can be 
used to identify diabetes such as blood glucose levels, retinal photography and plantar foot 
pressure. However, these tests do not identify cardiac autonomic neuropathy specifically [8-
10]. Ewing cardiac reflex test [11] is considered the gold standard tool for clinical assessment 
of CAN in patients with DM. Ewing battery constitutes a set of tests that measure the response 
of heart rate (HR) and blood pressure (BP) during diverse activities and positions of the 
patients. Unfortunately, the conventional Ewing battery test has a number of limitations. In 
particular, Ewing battery tests are often not suitable for all patients particularly those with 
cardiorespiratory comorbidity, frail or severely obese patients [7]. As a result of the difficulty 
of conducting the current tests and their lack of sensitivity using Ewing battery tests, CAN 
often remains undetected. This calls for more sensitive and accurate techniques that address 
the Ewing battery test shortcomings.  
A variety of factors such as heart rate variability (HRV) markers, genetic and family history 
risk factors can be used to identify the early stages of cardiac autonomic neuropathy in patients 
with DM. For instance, CAN causes impairment of the cardiac nerve fibres that innervate the 
heart and blood vessels, which leads to irregular heart rate [12, 13]. Therefore, the decrease in 
heart rate variability (HRV) is considered as an early stage of progressing CAN’s disease [14]. 
HRV is also decreased in diabetes mellitus type 1 and diabetes type 2. As a result, HRV is one 
of the approaches commonly used to evaluate the presence of CAN in patients. A number of 
previous studies have shown the effectiveness of HRV attributes for classifying cardiac 
pathology [15-17]. The majority of existing works are mainly focused on examining the time 
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and frequency domain attributes. However, the roles of the various markers in the prevalence 
and complications of CAN and associated diseases have remained to be further explored.  
Determining the capability of clinical variables such as HRV attributes as predictors of the 
CAN prevalence in the absence of complete information is an important area of research that 
has not been fully explored. The motivation to use clinical variables data is that they are richer 
than the results of the five Ewing battery tests, although, clinical variables are often easier to 
obtain in clinical practice than the Ewing battery tests. Despite the fact that research in early 
detection of CAN has recently received much attention, the question of evaluating the 
predictive value of various clinical attributes (e.g., genetic risk factors) as CAN prevalence 
remains open. This problem is further exacerbated as some key information useful for 
evaluating the predictive value of various clinical attributes is `often missing because not all 
five Ewing tests can always be administrated to patients. Therefore, the question of evaluating 
the predictive value of various clinical attributes (e.g., genetic risk factors) as CAN prevalence 
in the presence of incomplete information needs to be addressed. Therefore, there is a need to 
investigate the role of HRV markers for improving the predictive accuracy of the diagnosis of 
CAN progression particularly in the absence of a complete set of Ewing battery tests. In 
particular, a predictive model that combines Ewing battery tests with a subset of HRV markers 
that are optimal for enhancing the diagnosis of CAN is an area of interest to us. 
A model for predicting diabetes mellitus (DM) and cardiovascular disease (CVD) 
simultaneously is another open research problem [18]. CAN is a severe complication of 
diabetes mellitus (DM), which is strongly associated with increased risk of cardiovascular 
diseases (CVD) [19]. The clear co-relation between DM and CVD indicates the reason patients 
with diabetes mellitus are at high risk of cardiovascular diseases. This risk factor has motivated 
research on cardiovascular complications of diabetes. An interesting open question in this 
regard is how to predict diabetes mellitus and cardiovascular disease concurrently. This is a 
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significant problem and answering this research question is paramount. Given the fact that the 
impact of cardiovascular disease on patients with diabetes on public health management is 
already massive and is an upward trajectory, a model that is capable of predicting the co-
occurrence of diabetes mellitus (DM) and cardiovascular disease (CVD) simultaneously based 
on common risk factors is of practical use. 
1.2  Research Objective 
Many mechanisms have been proposed to identify the pathophysiology of CAN such as 
neurovascular insuﬃciency, autoimmune damage metabolic injury to nerve fibers and 
deﬁciency of neurovascular growth factors. These mechanisms, however, remain obscure [20]. 
The existing therapeutic approaches are furthermore still limited to prevention of the disease; 
this might be due to a defect in understanding the mechanisms that develop the disease [21]. 
 The overall aim of this thesis is to develop a system, which helps physicians to improve their 
ability in predicting CAN using machine-learning techniques. This thesis will particularly 
focus on the problems associated with the prediction of CAN based on various markers. CAN 
is also interrelated with multi diseases. Thus, this thesis will also concentrate on the associated 
diseases. The main aims of this thesis are to answer the following questions:  
1. How is Angiotensin-Converting Enzyme (ACE) gene’s polymorphism associated with 
the development of CAN?  
2. How do family history and EBT factors influence the prevalence of DM?  
3. How do HRV markers participate in improving CAN prediction?  
4. How can the probability of CAN occurrence be predicted? 
5. How can diabetes mellitus (DM) and cardiovascular disease (CVD) be predicted 
simultaneously?  
The scope of the first and second questions will engage the rural community of Australia.  
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1.3  Problem Statement and Motivations  
Cardiac Autonomic Neuropathy (CAN) is one of the most neglected diseases. Early fatigue, 
orthostatic hypotension, dizziness, syncope, presyncope, and exhaustion during exercise are 
the typical symptoms of CAN [4]. Unfortunately, these symptoms manifest a long time after 
the disease’s progress [22]. Although many methods have been proposed to diagnose and 
predict the pathophysiology of CAN, however, the prevalence of the disease is still increasing. 
This indicates that an advanced automated model and new risk factors for the prediction of 
CAN should be found. Diabetes mellitus (DM) moreover is known to be the leading cause of 
CAN as well as DM, which is highly correlated with an increased risk of cardiovascular diseases 
(CVD)[23]. This correlation clarifies why diabetes patients are at high risk for developing CVD 
diseases. Most of the existing studies have proposed different models to predict a single disease 
at a time. Therefore, there is a demand for predicting the associated diseases concurrently. 
The outcomes of other valuable tests, which may be already available for patients, 
motivate us to investigate their ability in the prediction of CAN. This thesis is therefore devoted 
to enhancing the prediction of CAN using new risk factors as well as the associated diseases. 
It will address the following sub-problems, which have not been prevalent in the literature: 
 The effect of ACE I/D polymorphism the development of CAN 
Genetic factors may play a prominent role in the development of CAN. The effect of genes 
on the incidence of the disease is varied. Although the effect of several genes has been 
investigated with CAN, the role of ACE I/D polymorphism in the development of the disease 
remains to be proven. The challenge faced in this study is how to explain the suspected 
association between ACE I/D polymorphism and CAN.  
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 The risk of family history and EBT in the prevalence of DM 
The primary cause of CAN is diabetes mellitus (DM). Due to the complex interrelated 
between CAN and DM, EBT combined with different risk factors such as family history might 
increase the risk of DM. The challenge faced in this study is to determine how these tests are 
associated with the prevalence of DM.  
 Improve the predictive accuracy of CAN especially with incomplete Ewing’s tests set.  
The traditional process of predicting CAN relies on EBT. However, EBT are not 
conclusive, while the availability of a full set of EBT is sometimes not possible for all patients. 
An important challenge addressed in this study is to determine the best way to improve the 
predictive accuracy of CAN with an incomplete set of EBT. 
 The probability of CAN occurrence. 
A wide range of models been proposed to predict CAN. These models, however, 
concentrated on only predicting disease categories. The degree of disease's progression is still 
unknown. The challenge faced in this study, therefore, is how to predict the probability of CAN 
progress. 
 The simultaneous prediction of DM and CVD.  
Diabetes mellitus (DM) and cardiovascular diseases (CVD) are significantly associated 
with CAN. Patients with DM are more likely to develop CVD and vice versa. Most of the 
existing methods are able to predict these diseases individually. The challenge faced in this 
study is how to simultaneously predict DM and CVD diseases.  
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1.4  Significance and Contributions  
Cardiac Autonomic Neuropathy (CAN) disease is one of the most unobserved diabetes mellitus 
(DM) complications. CAN and the associated diseases (DM and CVD) have shown significant 
contribution in a large number of mortality and morbidity cases worldwide. For instance, the 
rate of mortality in patients with DM is only 6% but 29% among patients with DM and CAN 
[24, 25]. There is substantial evidence that patients with CAN are between 1.55 and 2.14 times 
higher in mortality risk compared to those without [26]. In general, the clinical symptoms that 
are associated with CAN begin in the late stage of the disease [27]. Thus, trying to treat patients 
in a timely manner becomes a complicated process. Furthermore, about 25-50% of patients 
with diabetic autonomic neuropathy will die within 5-10 years of diagnosis [1]. In addition to 
its dangerous health consequences, the increase in the medical costs is an additional burden for 
the patients and their family members [28, 29]. It is therefore essential to provide guidelines 
for prevention, prediction, and management to handle CAN [30]. The ability to accurately and 
reliably predict CAN and the associated diseases is essential in preventing the incidence of 
CAN and the associated diseases. This is very significant in saving lives, providing timely 
intervention and also in the reduction of the diseases -related healthcare costs. 
This study has addressed the problem of predicting CAN’s disease using diverse factors 
such as heart rate variability (HRV) methods and genetic risk. The problem of CAN’s disease 
progression has also been solved in the present study. The effect of the traditional tests of CAN 
and genetic risk factors on the associated diseases has also been explored. The problem of 
predicting the associated diseases simultaneously has also been addressed in this study. These 
problems remain controversial, and the aim is therefore to maximize some given objectives 
such as accuracy of predicting, and identifying new tests, which are easier to perform, or 
alternatively minimizing specific objectives such as cost and prevalence of the disease and 
related diseases. Towards this end, this study makes the following contributions: 
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I. Provides a cross-sectional study to explore the association between ACE gene’s 
polymorphism and CAN’s disease. 
II. Provides a cross-sectional study to quantify the risk of diabetes family history, and 
Ewing’s Tests in the prevalence of Diabetics Mellitus (DM). 
III. The development of a new approach to predict CAN’s disease using HRV methods. 
IV. The development of a new model predicting the probability of CAN’s disease 
occurrence. 
V. The development of a new method that is able to reliably predict multi associated 
diseases simultaneously. 
The first contribution of the study explores the effect of ACE I/D polymorphism on the 
incidence of CAN. ACE I/D polymorphism plays a significant role in the development of 
diabetic neuropathies; however, the susceptibility of ACE I/D polymorphism with CAN is still 
controversial. This study, therefore, provides a cross-sectional study to explore the association 
between ACE I/D polymorphism and CAN and is useful in understanding the effects of the 
genes factors in CAN.  
As for the second contribution, the study quantifies the risk of a family history of 
diabetes, EBT and additional clinical tests on the prevalence of DM. Family history is shown 
as a significant risk factor for the prevalence of many diseases. EBT are also initial tests of 
CAN, which is significantly increased among DM patients. The effect of genetic factors on the 
prevalence of disease, however, differs among different racial/ethnic groups. Based on this, a 
cross-sectional study is provided to explore the effect of diabetes family history, and EBT on 
the prevalence of DM. This study is helpful to create greater awareness of the risk of family 
history and EBT in the prevalence of DM. The scope of the first and second contributions 
involves the rural community of Australia.  
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The third contribution of this thesis assesses the role of HRV methods in improving the 
prediction of CAN. HRV methods form a remarkable set of tests; usually collected for patients 
with different kinds of diseases. It is helpful in developing a predictive model that enables 
physicians to make more accurate and less invasive prognosis of CAN. This study, therefore, 
develops a predictive model to predict CAN using EBT combined with HRV methods. In 
particular, it predicts CAN with an incomplete set of Ewing’s tests.  
As for the fourth contribution, this study develops a predictive model to predict the 
probability of CAN occurrence using EBT. Predicting the probability of CAN occurrence is a 
critical issue. The predictive model assists physicians to predict the probability of CAN 
occurrence. It also helps physicians and patients to be aware of the risk of the disease.  
The fifth contribution of this study focuses on the diseases most associated with CAN 
(DM and CVD). These diseases are directly linked to CAN. Providing an efficient model to 
predict DM and CVD simultaneously helps to decrease the complications of these diseases 
such as CAN. In this contribution, the study develops a predictive model to predict these 
diseases simultaneously based on their common risk factors. This model assists doctors to 
predict DM and CVD simultaneously or individually to support better medical decision-making 
in clinics, thus reducing the complications. 
In summary, this study aims to make significant contributions, which help physicians to predict 
CAN, and the most associated diseases. 
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1.5  Research Methodology and Dataset 
1.5.1 Methodology  
The methodology is the general strategy of the thesis that elucidates the way of the thesis is to 
be undertaken. In general, methodology involves several theories such as the theoretical model, 
paradigm, phases, and used techniques. A wide variety of methodologies that include 
modeling, formal model (i.e., theoretical), experimental, simulation and statistical analysis 
have been used in computer science. A formal model with mathematical proof techniques, for 
the algorithm design and analysis, is paramount for the nature of the research being undertaken.   
In this study, both formal modeling and experimental analysis as a research strategy 
were used. In the cases where testing was simply impractical or prohibitively expensive, the 
simulation was used to evaluate, compare and optimize alternative designs, plans and policies. 
To quantify the feasibility and performance of the proposed approaches, the study implemented 
and verified the algorithms developed in the Waikato Environment for Knowledge Analysis 
(Weka) [31] and R [32, 33] platforms. Weka provides a set of machine learning methods 
developed in Java for data mining tasks. R platform also provided a straightforward group of 
coherent functions that were specifically designed to conduct data mining computation in a 
very intuitive way [34]. This study took advantage of such platforms due to the fully utilized 
computing power, the storage capacity of cloud computing and the graphical user interfaces. 
The study also applied simulations to examine and demonstrate the feasibility of the proposed 
solutions compared to similar competitive solutions.  
  To demonstrate the contribution of HRV methods in improving CAN prediction some 
vital steps were taken. First, the research area of predicting CAN was reviewed to provide an 
overview as well as formulate a valid problem statement. The research work was then justified 
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based on the review. Then, the proposed conceptual framework was developed using HRV 
methods combined with EBT.  
In the study, the same procedure as the above was repeated with the fourth and fifth 
sub-problems. For the fourth sub-problem, the research area of predicting CAN was reviewed 
then the problem was formulated. A predictive model was then proposed to predict the 
probability of CAN occurrence. The research area of predicting DM and CVD also reviewed 
the existing works and formulated the fifth sub-problem. Following this, the study developed 
a model based on common risk factors to predict such diseases simultaneously. 
Statistical analysis forms a central part of the data analytics (DA), which is essential to 
ensure that data are correctly interpreted. It is crucial as well to demonstrate that the apparent 
relationships are meaningful (or “significant, important”) and do not happen by chance. 
Applying statistical analysis to gain knowledge from past events decisively helps to understand 
the trend of the events and based on this understanding it is possible to predict the future. 
Statistical analysis allows us to estimate without prior knowledge of all the possible results. 
The statistical methods have been widely used in economics, health, life sciences, and 
agricultural science.  
In this study, the approach has been adopted as a strategy to solve the first and second 
sub-problems. The study considers outcomes as statistically significant only when 𝑃 < 0.05 as 
well as when the 95% confidence interval (CI) does not include the value 1. A significance 
level of 0.05 is employed for all analyses, and all 𝑃 values recorded were two-tailed. All 
investigations were based on hypothesis tests, either null hypothesis or alternative hypothesis. 
Null hypothesis was used to assess the validity of a claim made about a population. The 
alternative hypothesis was adopted, if the null hypothesis was inferred to be untrue. All 
statistical analyses were performed using SPSS software and R platform. SPSS is a software 
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package wildly used for statistical analysis in different fields such as data miners, social 
science, market research, health research, government, education researchers, survey 
companies, and marketing organizations.  
In the first sub-problem, the study investigated the relationship between ACE I/D 
polymorphism and CAN. Different types of statistical analysis tests and regression methods 
such as logistic regression were applied based on the null hypothesis or the alternative 
hypothesis. The research area within ACE I/D polymorphism was then reviewed, to provide an 
overview that led to investigating the role of ACE I/D polymorphism with CAN. 
 Similarly, in the second sub-problem, the study used diverse kinds of statistical 
analysis tests combined with regression methods to investigate the influence of family history 
and EBT on the prevalence of DM. Such tests and comparison were based on proposed 
hypotheses. The research area of the influence of family history was also reviewed to show the 
effectiveness and importance of the studied problem. 
1.5.2 Dataset  
 
In this study, a real well-known dataset (DiScRi) was used. DiScRi was collected from the 
diabetes complications screening research initiative at Charles Sturt University in Australia 
project by [35]. DiScRi was approved by the Ethics in Human Research Committee of the 
university. DiScRi is a large dataset, containing more than 200 types of tests for over 2000 
participants. The tests were related to CAN disease ranging from Ewing tests battery, peripheral 
nerve function, to attributes of different blood biochemistry and the Heart Rate Variability 
(HRV) methods. Demographic data for each patient such as sex, age, diabetic status were also 
registered. Different incidences of heart attack, diabetes, palpitations, and atrial fibrillation 
were also recorded. The procedure of collecting the data was as follows: all participants were 
instructed to stop smoking and avoid drinks such as coffee (caﬀeine) and alcohol for 24 hours 
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before taking the tests. They were also instructed to fast, starting from midnight before the day 
of tests. The tests were conducted from 9:00 am to 12:00 midday. 
1.6 Thesis Organization  
 The rest of the current thesis is organised as follows: Chapter 2 explores the various existing 
works that are related to CAN and the associated diseases. It also provides a brief literature 
review of the previous cases studied and reported. Chapter 3 presents the relationship between 
ACE I/D polymorphism and CAN. Chapter 4 contains the risk assessment of the family history 
factor and EBT in the prevalence of DM. Chapter 5 introduces a developed model to estimate 
the contribution of HRV features in the prediction of CAN. Chapter 6 presents a predictive 
model to predict the probability of CAN occurrence, while Chapter 7 includes the developed 
model to predict DM and CVD diseases simultaneously using their common risk factors. The 
summary of the significant findings and discussion of the achievements of this study as well as 
the highlights of possible future research directions are in chapter 8.  
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Chapter 2: Literature Review 
 
In order to place the problems studied in this thesis in the context of the existing literature, an 
extensive literature review has been undertaken. This chapter presents a comprehensive 
literature review of studies related to the research topic of the current study and their reported 
findings. .  
2.1  Background  
Diabetes mellitus (DM) represents the primary cause of cardiovascular autonomic 
neuropathy (CAN) [21]. The consequences of CAN among DM’s patients can be destructive 
[36]. The incidence of CAN results in impairment for cardiovascular autonomic control in the 
setting of diabetes after exclusion of other reasons [37]. This disease is considered a high-risk 
factor for mortality and morbidity [38, 39]. For instance, it is directly related to most cardiac 
disease cases of death among diabetics [40]. The disease has shown significant correlation with 
multi diseases such as silent myocardial ischemia [41], coronary artery disease [42], peri-
operative cardiovascular instability [43], stroke [44], and QT segment prolongation [45]. The 
disease has been revealed as a risk factor in the development of lower limb complications, 
which showed ability to change microvascular blood flow (MBF)[46]. It is believed that the 
disease participates in the pathogenesis of Charcot’s neuroarthropathy [47]. Despite the 
intensive effort to understand the disease , the pathogenesis of CAN has not been completely 
understood [48]. 
This chapter, reviews the most recent works that studied the prediction of CAN and also 
the latest studies that have inspected the role of ACE I/D polymorphism with the various forms 
of diabetic autonomic neuropathy (DAN). State-of-the-art studies related to the risk of family 
history of diabetes of the prevalence of the disease have also been reviewed. This chapter also 
reviews the most recent works about diseases most associated with CAN.  
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2.2  The Association between ACE I/D Polymorphism and CAN 
A significant number of studies have investigated the influence of ACE I/D polymorphism with 
various diseases. This section highlights the weaknesses of the previous studies conducted to 
evaluate the contribution of ACE I/D polymorphism to diabetic neuropathies, especially with 
CAN.  
For instance, Bhaskar, et al. [49] investigated the role of ACE and PPARG (peroxisome 
proliferator-activated receptor gamma) genes polymorphism in genetic susceptibility of 
diabetic nephropathy among the south Indian population. The study conducted on 54 patients 
with diabetic nephropathy and 67 control patients. Hardy-Weinberg equilibrium test was used 
to evaluate the distribution of genes polymorphism. Chi-Square test was applied to find identify 
the association and to analyse the distribution in genotype. Odds ratio was also calculated to 
measure the risk of genes’ polymorphism. Outcomes of the study demonstrated there was no 
significant difference in the frequencies’ distribution of ACE and PPARG genes polymorphism 
among the participants, and the genes, posed insignificant risk factors for genetic susceptibility 
of diabetic nephropathy. 
 Jayapalan, et al. [50] studied the relationship between ACE I/D polymorphism and 
diabetic nephropathy among multiethnic Malaysian subjects. For this study 393 participants 
were selected, with 137 of them as control (healthy), and 256 were with DM. The diabetic 
group was divided into normoalbuminuric, microalbuminuria, macroalbuminuria and End 
Stage Renal Failure (ESRF) based on the urinary albumin-creatinine ratio (ACR) and 
glomerular filtration rate (GFR). Many statistical analysis tests were used to compare the 
studied groups such as ANOVA test, Chi-square test, Kruskal-Wallis test, Levene’s test of 
homogeneity and Tukey’s HSD and Dunnett’s T3 post-hoc-test. Multinomial logistic 
regression was used to evaluate the risk of covariates. The conclusion of the study revealed that 
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there was no significant association between ACE I/D polymorphism and diabetic nephropathy 
groups among the study population. 
  Elhawary, et al. [51] examined the distribution of ACE I/D polymorphism among 
children/adolescents with diabetic nephropathy (DN) in Egypt. A total of 140 participants with 
T1DM were recruited to carry out the study. Of these, 80 participants were with DN, and the 
rest of the participants were without DN. The result of the study did not demonstrate any 
significant differences in the distribution of ACE and PstI polymorphisms between the 
examined groups.  
 Moţăţăianu, et al. [52] explored the association between cardiac autonomic neuropathy 
(CAN) and other micro- and macro-vascular complications as well as risk factors for patients 
with T2DM. There were 149 participants included, 91 of them without CAN, and 58 with CAN. 
Many statistical tests were used to compare the differences between the groups. For example, 
T-test was used to compare continuous variables, and Chi-Square to compare categorical 
variables. Logistic regression was also used to assess the independent associations between 
CAN and the included features. The outcome of the study showed the duration of diabetes, 
BMI, systolic blood pressure, lipid levels, and HBA1c are higher in patients with CAN. There 
is a significant association between CAN and retinopathy, peripheral neuropathy, ABI, and 
IMT.  
 Inanir, et al. [53] studied the relationship between ACE I/D polymorphism and diabetic 
peripheral neuropathy (DPN) among participants from Turkey. The study was conducted with 
516 participants with T2DM, 235 of them were with DPN while the rest were without DPN. 
The study revealed that the DD genotype was significantly associated with DPN . 
 Settin, et al. [54] assessed the relationship between ACE and MTHFR genetic 
polymorphisms and T2DM among 513 participants from Egypt. Of these, 202 participants were 
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with T2DM, 67 with diabetic retinopathy (DR), 93 with diabetic polyneuropathy (DPN), and 
47 with ischemic heart disease (IHD) and the rest were healthy. Different statistical analysis 
tests such as chi-square test, Fisher exact tests, and Hardy-Weinberg equilibrium were used to 
compare the assessed groups. Multivariate logistic regression was used to conduct the odds 
ratio (OR) of the included features. The study reported that the ACE DD genotype was a 
significant risk factor for DR and DPN. 
 Mansoor, et al. [55] investigated the association between ACE I/D polymorphism and 
diabetic peripheral neuropathy (DPN) among 1,103 participants from Islamabad in Pakistan. 
Of these, 496 participants were with T2DM, and 276 patients were with T2DM and DPN while 
the rest were healthy. The authors used several statistical analysis tests to perform this 
investigation such as Chi-squared test, Hardy–Weinberg equilibrium and odds ratios. The 
outcome of the study revealed that there was an insignificant association between the examined 
groups.  
 Zsom, et al. [56] evaluated the relationship between ACE I/D polymorphism and end-
stage renal disease (ESRD) among 533 elderly participants from Hungary. There were 245 
participants with end-stage renal disease (ESRD), 88 participants with mild, non-progressive 
chronic kidney disease (CKD) and 200 participants who were healthy. These participants were 
examined based on several groups such as primary renal glomerulonephritis, interstitial 
nephritis, hypertension-related CKD, diabetic nephropathy and inherited diseases. A set of 
statistical tests was used in the study such as Hardy–Weinberg equilibrium, and Chi-squared 
test. The result of analysis discovered significant differences in the distribution of ID and DD 
genotypes in the primary glomerulonephritis group. 
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Table 2-1 summarizes the studies reviewed above in this section. There is still an open gap, 
which needs to be bridged. The gap is about the role of ACE I/D polymorphism in developing 
CAN. The relationship between ACE I/D polymorphism and developing CAN has not been 
investigated so far.  
Table 2-1. A comparison of existing works of ACE gene 
Study Purpose of study Results 
Investigate with 
CAN  
[49] 
Investigated the role of ACE and PPARG genes 
with diabetic nephropathy in India 
Insignificant 
Association 
No 
[50] 
Explored the association between ACE gene 
I/D polymorphism and diabetic nephropathy 
groups in Malaysia 
Insignificant 
Association 
No 
[51] 
Searched the association between ACE I/D 
polymorphism with nephropathy in type 1 
diabetes in Egypt 
Insignificant 
Association 
No 
[52] 
Studied the association between CAN and other 
micro- and macrovascular complications and 
risk factors for type 2 diabetes 
A significant 
association 
No 
[53] 
Explored the association between ACE gene 
polymorphism and DPN among Turkish 
population. 
A significant 
association 
No 
[54] 
Studied the association between ACE gene I/D 
polymorphism and T2DM among the Egyptian 
population  
A significant 
association 
No 
[55] 
Reviewed ACE polymorphisms and DPN 
among (T2DM) patients in Pakistan 
Insignificant 
Association 
No 
[56] 
Investigated the association between ACE gene 
I/D polymorphism and ESRD among subjects 
from Hungary. 
A significant 
association 
No 
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2.3  The Risk of FH and EBT for the Prevalence of DM  
 
Family history is a non-modifiable risk factor for diabetes mellitus (DM), which very strongly 
influences the prevalence of the disease. This section provides an overview of the previous 
studies that were conducted to evaluate the risk of family history of diabetes and Ewing’s tests 
for the prevalence of disease. 
For instance, Zhang, et al. [57] investigated the association between family history risk 
categories and the prevalence of diabetes mellitus (DM) for 3,6281 participants from China. 
The participants were divided into three groups: average (FH0), moderate (FH1), and high 
(FH2). The FH0 group included all participants without DM in their first generation relatives. 
The FH1 group contained all participants with DM in their first-generation relative. The HF2 
group involved all participants of at least two generations of their first-generation relative with 
diabetes. The results from the FH1 group and the HF2 group significantly contributed to the 
prevalence of the disease with (odds = 2.86; P < 0.05) and (odds = 6.16; P < 0.05) respectively. 
The categories of family history risk have marked association with the prevalence of DM. 
 Du, et al. [58] also assessed the role of family history level for the prevalence of diabetes 
mellitus (DM) among China’s high-risk population. The study was conducted on 9,754 adults, 
who divided into three groups based on family history (mild, moderate, and high). The mild 
group included 6,756 adults with no family history or one of their second-generation relatives 
with DM. The moderate group consisted of 2,443 adults with one of their first and second-
generation relatives with DM, or at least two of their second-generation relatives with DM. The 
high-risk group comprised 555 adults with at least second generation relatives who had DM 
from the same lineage. The insulin secretion and sensitivity in normal glucose tolerance NGT 
association with the marked family history was also investigated. Many statistical analyses 
tests such as chi-squared test, ANOVA, Shapiro–Wilk test, Post hoc analysis, Dunnett’s test 
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and logistic regression were used to conduct the study. The evaluation showed the prevalence 
of DM had increased with the increase in the level of family history, moderate group (odds = 
1.27; P <0.05) and in the high group (odds = 1.69; P <0.05). 
 Zhang, et al. [59] examined the contribution of family history, the insulin sensitivity 
and insulin secretion to the prevalence of diabetes mellitus (DM) among 9,756 participants 
from Shanghai in China. Of these, 2075 participants were with parental DM, 547 participants 
were siblings DM and the rest without a family history. A number of statistical tests such as 
Shapiro-Wilk W-test, One-way ANOVA and chi-squared tests, Dunnett’s test and Logistic 
regression were used to conduct the study. The results of examination revealed that the sibling 
history group was highly associated with DM risk compared to other groups with (odds= 1.53; 
P <0.05).  
Another study in [60] investigated the influence of family history of diabetes mellitus 
(DM) and abdominal obesity on the prevalence of the disease. Three datasets for men and 
women from Korea were used to conduct the study. Number statistical analysis tests were used 
to carry out the study such as logistic regression. The outcomes of the study disclosed that 
family history of diabetes was a strong risk factor among men with (odds = 1.508; P = 0.003) 
in a 2001 dataset, (odds = 3.351; P = 0.003) in a 2005 dataset, and (odds = 7.302; P = 0.003) 
in a 2010 dataset, whereas it was not a risk factor among women.  
 Valdez, et al. [61] also investigated the association between family history of diabetes 
mellitus (DM) and the prevalence of disease for 16,388 adults from USA. The adults were 
separated into three groups: average, moderate and high. The average group included all adults 
without a family history or at least one of their second-generation relatives had DM. The 
moderate group involved all adults with one of their first and second-generation relatives or 
only first generation with DM, at least two second-generation relatives with DM. The high-
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level group consisted of all adults with at least two of their first-generation, or one of their first-
generation and at least two second-generation relatives with DM. Multiple logistic regression 
was used to conduct risk of the included features in the study. The result of the study 
demonstrated there was a significant association between family history and the prevalence of 
DM. In comparison with the average group, the moderate and high groups were at significantly 
higher risk of developing the disease with (odds = 2.3 and odds = 5.5) respectively.  
A different study in [62] examined the effect of family history of diabetes mellitus 
(DM) on the prevalence of disease among 4,482 adults Sri Lankans’. Of these, 535 adults were 
with DM, and the rest were without DM. Family history was evaluated at three levels based on 
the parents, grandparents (paternal and maternal) and siblings. Several statistical analysis tests 
were conducted to fulfil the study requirements such as logistic regression, z-test, and Student’s 
t-test or analysis of variance (ANOVA). In comparison with adults without a family history, 
the prevalence of diabetes in the adults with family history was significantly higher. The study 
showed that the family history factor was a significant risk factor for the disease with (odds = 
3.35, P = 0.05).  
Another study by Gupta, et al. [63] was conducted to investigate the impact of family 
history of diabetes mellitus (DM) on developing the disease among the “Aggarwal” population 
of Delhi, India. The study included 362 participants, 200 of whom were with DM, and the rest 
were controls. Of these, there were 184 participants with family history and 178 without a 
family history. Logistic regression was employed to estimate the odds ratio. The study revealed 
there was a significant association between the prevalence of disease and existence of family 
history with (odds = 2.3; P = 0.000).  
 Sakurai, et al. [64] evaluated the contribution of family history of diabetes mellitus 
(DM) on the disease incidence among 3,517 Japanese. Of these, there were 630 participants 
with positive family history, while the rest were with negative history. Hazard ratios were used 
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to calculate the effect of included features. The outcome of the study showed the presence of 
family history significantly participated in developing the disease with (HR = 1.82; P <0.05).  
One of the most recent studies in Australia was by Magliano, et al. [65]. The study 
aimed to study the effect of glucose, health behaviors on the incidence of diabetes based on 
longitudinal data from the Australian diabetes, obesity and lifestyle study (AusDiab). It 
followed up on 5582 adults for five years (209 were with diabetes and 5,373 without). 
Multivariate logistic regression was used to conduct the study. The result revealed that the 
presence of family history significantly contributed to the development of diabetes with (odds 
= 1.82; P <0.05).  
Cugati, et al. [66] also estimated the prevalence of diabetes mellitus (DM) based on 
metabolic syndrome risk factors and family history among Australians. The study used 
longitudinal data of 2,123 participants for 10 years from the Blue Mountains Eye Study. 
Multivariate logistic regression was applied to carry out the study. The outcome of the study 
showed that incidence of diabetes increased with the existence of family history with (odds = 
1.7; P <0.05).  
Although the above-provided studies investigated the influence of family history of 
diabetes on the prevalence of disease as listed in Table 2-2. The risk of a family history of 
diabetes, however, varies among different populations. As for the studies carried out among 
the Australian population did no cover the risk of Ewing’ tests on diabetes prevalence. 
Furthermore, in comparison with patients without DM, there were few patients with DM in in 
[65]. It led to unbalanced data which affected the estimation of the study. As for the study in 
[66] was conducted only on participants aged more than 49 years. 
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Table 2-2. Summarizes the risk of an FH of diabetes among various populations 
Study Purpose of study 
The 
outcome 
Risk of family history 
[57] Investigated the association between family 
history of diabetes and the prevalence of disease 
among Chinese population 
Positive 
Moderate group (odds 
= 2.86; P < 0.05). High 
group (odds = 6.16; P < 
0.05) 
[58] Evaluated the impact of family history risk level 
of diabetes on the prevalence of disease among 
Chinese population ( a cohort in Shanghai) 
Positive 
Moderate group (odds 
= 1.27; P <0.05)  
High group (odds = 
1.69; P <0.05).  
[59] Examined the influence of family history of 
diabetes on the prevalence of disease as well as 
among Shanghai population in China 
Positive (odds= 1.53; P <0.05). 
[60] Studied the effect of family history and 
abdominal obesity on the prevalence of DM 
among the Korean population 
Positive 
In 2001 (odds = 1.508; 
P = 0.003).  
In 2005(odds = 3.351; 
P = 0.003). In 2010 
(odds = 7.302; P = 
0.003)  
[61]  Inspected the relationship between family history 
and diabetes among the USA population Positive 
Moderate group (odds 
= 2.3). High group 
(odds = 5.5) 
[62] Investigated the role of diabetes family history in 
the prevalence of disease among Sri Lankan ’ 
adults 
Positive. (odds = 3.35, P = 0.05). 
[63] Estimated the contribution of family history of 
diabetes to the prevalence of disease among the 
“Aggarwal” population of Delhi, India 
Positive (odds = 2.3; P = 0.000). 
[64] Assessed the effect of family history of diabetes 
on the disease’s occurrence among the Japanese 
population  
Positive (HR = 1.82; P <0.05) 
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[65] Examined the impact of Glucose, health 
behaviors on the incidence of diabetes among the 
Australian population 
Positive (odds = 1.82; P <0.05). 
[66] Studied the prevalence of diabetes based on 
metabolic syndrome risk factors and family 
history among the Australian population 
Positive (odds = 1.7; P <0.05). 
 
2.4  The Prediction of CAN  
This section underlines the shortage of existing models in predicting CAN. Many studies have 
proposed different data mining algorithms to predict CAN's disease and most of them have 
presented in Table 2-3.  
For example, Jelinek, et al. [67] investigated the neurological diagnostics of a CAN based on 
the five Ewing test attributes. In this research, the authors compared the effectiveness of a wide 
range of decision tree classification methods such as J48, NBTree, REPtree, and SimpleCart. 
They used the highest accuracy classifier with a meta-ensemble classifier such as AdaBoost, 
Bagging, or Decorate, and then added a combination for multi ensemble classifiers to improve 
the accuracy. Random forest overcame all other base classifiers. The best-obtained result was 
by Decorate based Random forest ensemble ROC= 0.984.  
An early method to improve the classification of CAN's disease by combining Ewing 
test features with additional attributes along with clinical data such as age, sex , diabetes status, 
blood pressure (BP), body-mass index (BMI), blood glucose level (BGL), and cholesterol 
profile was used in [68]. The authors used multi-level ensemble classifiers and feature selection 
based on Random Forest. These combinations achieved an area under the curve (AUC) of 0.997 
for classifying presence of CAN's disease regardless of CAN progression (CAN2), 0.994 for 
CAN3 when the groups were represented by no CAN, early and definite CAN and 0.990 when 
a severe CAN group or atypical classification (CAN4). 
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  Abawajy, et al. [7] took a different approach to [68], which was the Automated Iterative 
Multitier Ensemble (AIME), which enhanced the accuracy of CAN's disease classification by 
using blood biochemistry features and the Ewing test results. The AMIE employed a range of 
ensemble classifiers in each layer. Therefore the ensemble worked as an integral part of another 
ensemble. The experimental results showed that several blood biochemistry features had high 
impact, which could be used to complete the Ewing tests in case the Ewing battery results were 
incomplete. The AIME work showed high accuracy, at 99.57%.  
 Huda, et al. [69] proposed a hybrid of wrapper filter feature selection to explore a novel 
features and decision rules to detect cardiovascular autonomic neuropathy (CAN). The 
proposed feature method combined Maximum Relevance, MR filter and wrapper (Artificial 
Neural Net Input Gain Measurement Approximation ANNIGMA) in one approach called MR-
ANNIGMA. The advantages of the proposed method are: it takes advantage of both filter and 
wrapper methods. Then, standard decision trees classifier is used to classify the most important 
features selected by (MR-ANNIGMA). The experiment used Ewing tests and ECG features 
from diabetes complications screening research initiative (DiScRi) dataset.  
 Kelarev, et al. [70] proposed ensembles classifiers based on Ripple down Rules to 
predict the cardiovascular autonomic neuropathy (CAN). Many ensembles have been 
investigated such as AdaBoost, Bagging, Dagging, Decorate, Grading, MultiBoosting, 
Stacking, AdaBoost of Bagging and Consensus functions. The experiments were tested on the 
five Ewing tests from diabetes complications screening research initiative (DiScRi) dataset. A 
10-fold cross-validation test was used to assess the performance. The highest obtained accuracy 
was by AdaBoost of Bagging ensemble classifier at 94.6%. 
 Kelarev, et al. [71] proposed the monitoring of patients with diabetes in pervasive 
healthcare. To address this issue, the work proposed ensemble classifiers based on decision 
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trees classifiers. The work investigated many ensembles of classifiers based on decision trees 
classifiers and chose the highly accurate one. The investigated ensembles were AdaBoost, 
Bagging, Decorate, Grading, MultiBoost, Stacking, AdaBoost of Bagging, MultiBoost of 
Bagging and HBGF. The experiments used Ewing test and ECG features from diabetes 
complications screening research initiative (DiScRi) dataset. In order to assess the 
performance, a 10-fold cross-validation was used. The highest obtained accuracy was by 
AdaBoost of bagging ensemble based on decision tree J48 94.84%.  
 Abawajy, et al. [72] proposed Multi-tier Ensemble classifiers to diagnose 
cardiovascular autonomic neuropathy (CAN) based on a subset of Ewing test battery and QRS 
features. Many base classifiers were investigated such as ADTree, J48, LibSVM, NBTree, 
Random Forest and SMO. Moreover, a number of ensemble classifiers were investigated based 
on Random Forest such as AdaBoost, Bagging, Dagging, Grading MultiBoost, and Stacking. 
Further, to increase the accuracy, a combination of two ensembles based on random forest was 
used. To overcome the fitting in dataset, a 10-fold cross-validation was used in all experiments. 
The best-obtained result was 97.74% by the Combination of AdaBoost and Bagging.  
Recently, Jelinek, et al. [73] proposed an iterative Multi-Layer Attributes Selection and 
Classification (MLASC) model, for diagnosing CAN’s disease using Ewing battery tests 
combined with HRV tests. The work proposed a new feature selection method called Double 
Wrapper Subset Evaluator with Particle Swarm Optimisation (DWSE-PSO). The proposed 
feature selection (DWSE-PSO) was incorporated within MLASC and compared with several 
existing feature selection methods applied in Weka such as Wrapper Subset Evaluator (WSE), 
Classifier Attribute Evaluator (CAE), and Information Gain Attribute Evaluator (IGAE) to 
assess attributes. Their experimental results showed that the performance of the DWS-PESO 
was better compared to the other approaches investigated in the study. The models were 
evaluated using 5*2 cross validation paradigm. Three datasets with different classes used in 
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the experiments were CAN2, CAN3, and CAN4. The best results were ROC = 0.96 for CAN2, 
ROC = 0.95 for CAN3, and ROC = 0.94 for CAN4.  
Despite the excellent performance of the proposed models in [7, 67-72], these models 
did not assess the contribution of HRV methods in predicting CAN. There is only one model 
involved in HRV methods in [73]. The model, however, did not disclose the essential methods 
of HRV that would assist in improving the prediction of CAN. The problem of incomplete EBT 
also was not addressed. Moreover, all the works in [7, 67-73] were proposed to predict CAN 
categories. They did not address the problem of predicting the probability of CAN. 
Table 2-3. Summarizes the different works of predicting CAN. 
Study Purpose of study 
Using 
HRV 
methods? 
Predicting a 
probability of 
CAN 
occurrence? 
[7]  Proposed a multitier ensembles model called 
Automated Iterative Multitier Ensemble (AIME) 
to enhance the prediction’s accuracy of CAN’s 
disease by using blood biochemistry features with 
Ewing’s tests. 
No No 
[67] Investigates the contribution of neurological 
diagnostics of CAN’s disease combined with 
Ewing’s tests 
No No 
[68] Improves the classification of CAN’s disease by 
combining Ewing’s test with additional features. 
No No 
[69]  Proposed a hybrid of wrapper filter feature 
selection to explore a novel features and decision 
rules to detect cardiovascular autonomic 
neuropathy (CAN). 
No No 
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[70] Proposed ensembles classifiers based on Ripple 
down Rules to predict the cardiovascular 
autonomic neuropathy (CAN). 
No No 
[71]  Proposed the monitoring of patients with diabetes 
in pervasive healthcare. 
No No 
[72]  Proposed a Multi-tier Ensemble classifier to 
diagnose cardiovascular autonomic neuropathy 
(CAN) based on a subset of Ewing test battery 
and QRS features. 
No No 
[74]. Proposed a Multi-Layer Attributes Selection and 
Classification (MLASC) model, for diagnosis of 
cardiac Autonomic Neuropathy using Ewing 
battery tests combined with HRV features. 
Yes No 
  
2.5  Review of Associated Diseases Prediction Models  
A large number of models have been proposed to predict diabetes mellitus (DM) and 
cardiovascular disease (CVD) as listed in Table 2-4.  
For example, Alghamdi, et al. [75] proposed a model to predict DM using ensemble 
machine learning method based on multi classifiers. Thet investigated base classifiers were 
Naïve Bayes tree, random forest, and logistic model tree. Data of 32,555 participants from 
Henry Ford exercIse Testing (FIT) project were used to evaluate the model [76]. The best 
outcome for the constructed model was (AUC = 0.92).  
 Samant and Agarwal [77] designed a model to detect diabetes mellitus (DM) based on 
iris images. Several classifiers such as support vector machine, binary tree, adaptive boosting, 
neural network, random forest and generalized linear models were examined for inclusion in 
the model. They evaluated the model using data of 338 participants (180 were with diabetes 
and 158 were control). The highest obtained accuracy was by random forest with 89.63%.  
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Another work in [78] proposed intelligible support vector machines for diagnosis of 
diabetes mellitus (DM) using a real-life diabetes dataset. Many rule extracting methods have 
also been used to extract rules from SVM such as SQRex-SVM and eclectic rule extraction. 
The best prediction accuracy of the model was 94%. Wu, et al. [79] proposed a double-level 
algorithms prediction model to diagnose diabetes mellitus (DM) based on the improved K-
means algorithm and the logistic regression algorithm. The model was evaluated on the Pima 
Indians diabetes dataset. In comparison with the accuracy of prediction of investigated studies 
the proposed model showed an increased accuracy of 3.04%.  
 As for CVD disease, Das, et al. [80] applied neural network ensembles in identifying 
heart disease using Cleveland heart disease dataset (CHDD). The accuracy of the proposed 
method was 89.01%. Uyar and İlhan [81] proposed a genetic algorithm (GA) based on trained 
recurrent fuzzy neural networks (RFNN) to detect heart disease. They evaluated the algorithm 
using Cleveland heart disease dataset (CHDD). The predictive accuracy of the algorithm was 
97.78%. Amiri and Armano [82] used classification and regression tree to develop an early 
diagnosis model of heart disease based on heart sounds. The model’s evaluation is based on 
116 heart sound signals dataset. The accuracy of the developed model was very high at 99.14%. 
Masetic and Subasi [83] proposed a model to predict congestive heart failure using random 
forest method based on ECG signal. Several classifiers such as k-nearest neighbour, C4.5 
decision tree, artificial neural networks, support vector machine, and random forest were 
examined. Data of 15 participants from Beth Israel Deaconess Medical Centre (BIDMC) 
Congestive Heart Failure (CHF) database was used to evaluate the study. The best accuracy 
was by was by random forest with 100%. Another study in [84] offered a system to predict 
Congestive Heart Failure (CHF) based on UCMIFS selector and support vector machine 
(SVM) . The study is conducted using data from the congestive heart failure (CHF) and normal 
sinus rhythm (NSR) database. The outcome of the study showed high accuracy of 97.59%.  
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Despite the outstanding performances of the models in the literature, they proposed to 
predictonly a single disease, either CVD or DM. According to the direct association between 
CVD and DM, patients often \ suffer from more than one single disease at the same time. 
Therefore, these models are inadequate for predicting DM and CVD simultaneously. 
Table 2-4. Summary of the related works of predicting CVD and DM. 
Study Purpose of study 
Predict CVD and DM 
simultaneously? 
[75] 
Predicting diabetes mellitus using 
ensemble machine learning method based 
on multi classifiers 
No 
[77] 
Designing a model to detect diabetes 
disease based on iris images 
No 
[78] 
Proposing an Intelligible Support Vector 
Machine to diagnose diabetes mellitus 
using a real-life diabetes dataset. 
No 
[79] 
Proposing double-level algorithms 
prediction model to diagnose diabetes 
based on the improved K-means algorithm 
and the logistic regression algorithm 
No 
[80] 
Applying neural network ensembles in 
identifying heart disease using Cleveland 
Heart Disease Dataset (CHDD). 
No 
[81] 
Proposing a genetic algorithm (GA) based 
on trained recurrent fuzzy neural networks 
(RFNN) to detect heart diseases. 
No 
[83] 
Proposing a model to predict Congestive 
heart failure using random forest method 
No 
[84] 
Suggesting a system to predict Congestive 
Heart Failure (CHF) using UCMIFS 
selector and support vector machine 
(SVM) 
No 
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2.6  Chapter summary  
This chapter reviewed the previous related works in the field of the current study and also 
outlined the most recent studies on the role of ACE I/D polymorphisms with diabetic 
neuropathy. This chapter also reviewed a number of studies, related to the impact of family 
history of diabetes on the prevalence of the disease. Several related works to predict CAN’s 
disease were also re-evaluated. The most recent work to predict DM or CVD was also 
reviewed. Finally, it was found that the reviewed studies did not address the significant sub-
problems that this study addressed. 
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Chapter 3: The Relationship between Angiotensin 
Converting Enzyme Gene Polymorphism and Cardiac 
Autonomic Neuropathy  
This chapter analyzes the association between genes and cardiovascular autonomic neuropathy 
(CAN) disease. In particular, we focus on how Angiotensin-Converting Enzyme (ACE) gene 
polymorphism and additional clinical features are associated with the incidence of CAN. We 
use a cross-sectional study to assess the association between ACE I/D polymorphism and CAN.  
3.1 Introduction  
Cardiac Autonomic Neuropathy (CAN) is a multifactorial disease that occurs because of the 
interactions between various genes and environmental factors [48]. Genes play a significant 
role in the incidence of CAN [85]. Identifying the risk of genetic factors essentially helps in 
both increasing the understanding of the pathogenetic mechanisms of the disease and finding 
biomarkers of risk prediction and response to therapeutic intervention [48]. Thus, the 
susceptibility of genetic risk factors with CAN should be investigated. 
Many genes have been investigated with CAN. For example, Transcription factor 7-
like 2 (TCF7L2), T393C single nucleotide and Glutathione S-transferases (GSTs) genes have 
shown a strong correlation with the presence of CAN [86-88]. Each gene, however, has a 
different effect on the incidence of CAN disease. Angiotensin-Converting Enzyme (ACE) gene 
is considered one of the genes that play an essential role in the development of many diseases. 
Although ACE insertion/deletion (I/D) polymorphism has shown a direct association with 
diabetes neuropathies in many studies such as [49, 89, 90], the role of ACE I/D polymorphism 
with CAN has not been investigated yet. 
Applying statistical analysis tests in analyzing medical data that collected for diabetic has 
a long list of advantages. For example, it improves patients' well-being and decreases the 
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morbidity and mortality that are related to cardiac arrhythmias in diabetes. This chapter, 
provides a cross-sectional study to investigate the role of ACE I/D polymorphism, combined 
with EBT, cholesterol blood biochemistry features and the demographic data of patients with 
CAN. In particular, we performed the present study on participants from the rural community 
of Australia. 
The design of this chapter is as follows: the description of the problem and motivation is 
explained in Section 3.2. A brief background and the significance of ACE gene are provided 
in Section 3.3. The methodology used is described in Section 3.4 while Section 3.5 presents all 
the obtained results. Chapter summary is provided in Section 3.6.  
3.2  Problem Overview and Motivations  
As stated in the introduction section, CAN is a multifactorial disorder due to the complex 
interactions between various genes and environmental factors. The susceptibility of ACE I/D 
polymorphism was extensively investigated with several types of diabetes neuropathies such 
as diabetic nephropathy (DN) and diabetic peripheral neuropathy (DPN).  
For example, Bhaskar, et al. [49] examined the role of ACE I/D polymorphism in the 
development of diabetic nephropathy among the south Indian population. Jayapalan, et al. [50] 
inspected the relationship between ACE I/D polymorphism and diabetic nephropathy among 
multi-ethnic Malaysian subjects. Another study by [91] also evaluated the influence of ACE 
I/D polymorphism on the incidence of diabetic nephropathy (DN) among the Chinese 
population. Jayapalan, et al. [50] studied the association between ACE I/D polymorphism and 
diabetic nephropathy among multiethnic Malaysian subjects. A meta-analysis study using 
seven previous studies was provided by [89] to analyze the relation between ACE I/D 
polymorphism and the risk of diabetic peripheral neuropathy (DPN) among publication 
(PubMed and EMBASE) databases. Inanir, et al. [53] also assessed the relationship between 
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ACE I/D polymorphism and diabetic peripheral neuropathy (DPN) among participants in 
Turkey. Another study by [56] investigated the relationship between ACE I/D polymorphism 
and end-stage renal disease (ESRD) among elderly patients from Hungary.  
Despite a large number of studies have been done to investigate the relationship between 
ACE I/D polymorphism and DN and DPN; there is a shortage in studies that evaluate the 
relation between ACE I/D polymorphism and CAN. The influence of ACE I/D polymorphism 
on developing CAN remains obscure and needs to be proven [92]. There is therefore a need to 
clarify the role of ACE I/D polymorphism in the prevalence of CAN’s disease.  
3.3  Angiotensin-Converting Enzyme Gene  
The ACE gene provides instructions for making the angiotensin-converting enzyme. This 
enzyme is considered a critical component of Renin-Angiotensin (RAS) and Kinin-Kallikrein 
(KKS) systems [93, 94]. These systems play an essential role in the human body. For instance, 
RAS regulates the blood pressure and balances the fluids level and salts [95, 96]. KKS controls 
the vasodilation, cardioprotection, inflammation, vascular permeability, smooth muscle 
contraction, coagulation and pain [97]. The location of the ACE gene is in chromosome 17q23 
and comprises 26 exons and 25 introns as presented in Figure 3-1 [98, 99].  
 
Figure 3-1. ACE gene location chromosome 17q23 
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3.3.1  ACE Gene Polymorphism  
The variation of Angiotensin-Converting Enzyme (ACE) is called ACE I/D polymorphism 
[100]. The polymorphism describes the activity of ACE as well as determines serum levels. 
This polymorphism characterizes by Insertion (I) allele or Deletion (D) allele of a 287-base 
pair repeated within intron 16 of the gene [101]. The identification of ACE gene polymorphism 
relies on the presence of I allele or absence (D allele) as listed in Table 3-1 [102]. Each human 
being has a couple of Alleles, either both Alleles are (II), or (DD) or one Allele for each (ID) 
[103]. The DD alleles indicate the highest level of Enzyme; whereas ID alleles and II alleles 
represent the medium level and the initial level of the Enzyme respectively. 
Table 3-1. ACE I/D Polymorphism 
ACE I/D polymorphism Description 
II Two insertion (I) allele 
ID One insertion (I) allele and one deletion (D) allele 
DD Two deletion (D) allele 
 
3.3.2 The Significance of the ACE Gene  
Angiotensin-converting Enzyme (ACE) gene plays a vital role in many functions in the human 
body especially in RSR as presented in Figure 3-2 [104]. For example, the ACE gene controls 
blood pressure by converting angiotensin I into angiotensin II and can cut proteins [105]. By 
cutting protein angiotensin I at a specific location, RAS converts the angiotensin I into II, that 
narrows the blood vessels, subsequently increases the blood pressure [106]. The ACE gene 
mainly contributes to the production of aldosterone hormone, which causes absorption of water 
and salts in the kidney [107]. High levels of angiotensin II may change the regulation of glucose 
and insulin which could increase the risk of diabetes [108].  
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On the other hand, the ACE gene is capable of cleaving other proteins such as 
Bradykinin2, which broadens blood vessels and decreases the blood pressure [109]. In addition 
to the important role of the ACE gene in RSR, it has intensely studied due to its essential role 
in various diseases.  
 
Figure 3-2. Renin–Angiotensin System (RAS)  
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3.4  Methodology 
The methodology refers to the systematic, theoretical analysis of the methods used to 
implement the current study. Figure 3-3. describes the general steps that are used to carry out 
the current study. 
 
Figure 3-3. The framework of the present study 
3.4.1 Dataset Collection and Features Extraction 
A real dataset from the diabetes complications screening research initiative project (DiScRi) 
was used in the current study. This dataset was organized by Charles Strut University [35]. 
DiScRi collects and analyses according to the policies of the Ethics in Human Research 
Committee (HRECs) of the university. The DiScRi contains more than 200 tests related to 
CAN. The current study included only EBT, ACE I/D polymorphism, cholesterol blood 
biochemistry features, and demographic data. All the included features are listed in Tables 3.2 
to 3.4. Due to the availability of the ACE gene information, only 299 participants were involved 
 41 
 
in this study. For the comparison analysis, this study divided the patients into two groups based 
on the presence of CAN. The ﬁrst group was CAN-, including all participants with the Normal 
category. The second group was CAN+ and comprised all participants with Early, Deﬁnite, 
Atypical and Severe categories. Among the 299 participants, there were 132 participants with 
CAN- and 167 participants with CAN+. 
Table 3- 2. Ewing Battery Tests 
Variable Description 
LSHR “Lying to Standing Heart Rate change.” 
DBHR “Deep Breathing Heart Rate change.” 
VAHR “Valsalva manoeuvre Heart Rate change” 
HGBP “Hand Grip Blood Pressure change.” 
LSBP “Lying to Standing Blood Pressure change.” 
 
Table 3-3. The cholesterol blood biochemistry features 
Variable Description 
HDL High-density lipoprotein measured in (mmol/L) 
LDL Low-density lipoprotein measured in (mmol/L) 
TC Total cholesterol measured in (mmol/L) 
Triglyceride Level of triglyceride in the blood measured in (mmol/L) 
HbA1c  Indicates blood sugar level control over time measured in 
(mmol/L)  
 
Table 3-4. The demographic clinical data 
Variable Description 
Gender Male / Female 
Age  No. of years 
Waist Circumference Excess fat around the waist 
BMI Body Mass Index 
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3.4.2 Univariate Analysis and Regression Methods  
A series of intensive statistical tests was applied in the current study using R language and 
SPSS software version 24 (SPSS, Inc., Chicago, IL, USA), as presented in Table 3-5.  
Table 3-5. A Statistics Analysis Tests. 
Test Type Variables 
Student’s T-Tests TC, LDL  
Wilcoxon-Mann-Whitney Test LSHR, HbA1c, Triglyceride, HDL, Waist 
Circumference, BMI, DBHR, VAHR, HGBP, 
LSBP, Age 
Shapiro–Wilk Test All continuous variables. 
Chi-square Test Gender  
Hardy – Weinberg equilibrium and 
Chi-square Tests 
ACE I/D polymorphism 
Univariate Logistic Regression All variables. 
Multivariate Logistic Regression  All variables.  
 
3.4.2.1 Univariate Analysis 
The univariate analysis was used to compare the participants with and without CAN’s disease 
to understand their characteristics. For instance, Chi-square test was applied to describe the 
variations between categorical features (expressed as number and percentage). Student’s T-
tests were used to evaluate the differences of the continuous features with a normal distribution 
(expressed as mean ± SD). Wilcoxon-Mann-Whitney test was employed to measure the 
differences between non-parametric features (expressed as median, range). Hardy Weinberg 
equilibrium theorem was used to calculate the distribution of polymorphism and Allele 
frequencies; then Chi-square test was used to quantify the differences in the distribution of 
ACE I/D polymorphism and Alleles for the examined groups. Shapiro-Wilk test was performed 
to estimate the normality of continuous features.  
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3.4.2.2 Regression Methods 
Logistic regression is one of the most common types of regression methods was developed by 
[110]. This method is widely used in various fields of life [111]. In general, logistic regression 
is used to explore the relationship between independent and dependent variables. It a statistical 
method which can be used when the dependent variable is categorical (dichotomous variable 
or Multinomial variable). Unlike linear regression, logistic regression does not require a linear 
relationship between the independent and outcome variables. The general formula of logistic 
regression can be expressed as follows:  
log (
𝜋
1 −  𝜋
) =  𝛽0 +  𝛽1𝑥1 + 𝛽2𝑥2 + ⋯ 𝛽𝑛𝑥𝑛  (1). 
where: 
 𝜋 represents the probability of an outcome (dependent variable) occurrence based on the 
independent variables. 𝛽 indicates the regression coefficients of each included independent 
variable. 
One of the most significant advantages of using logistic regression is the odds ratio, 
which provides a readily interpretable and easily estimated compromise [112]. The odds ratio 
is the exponential function of the regression coefficient 𝛽. An odds ratio (OR) is used to 
measure the association between an independent variable and a dependent variable [113]. The 
OR represents the odds that an outcome will occur given a particular exposure, compared to 
the odds of the outcome occurring in the absence of that exposure. The following formula 
represents the general equation of odds ratio according to [113]: 
Odds Ratio =  
𝑋 𝑌⁄
𝑍 𝑊⁄
 =  𝑋 ∗ 𝑊 𝑍 ∗ 𝑌⁄   (2). 
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where:  
 X denotes the number of exposed cases; Z represents the number of exposed non-cases; Y 
refers to the number of unexposed cases and W indicates the number of unexposed non-cases. 
Several studies have used logistic regression to explore the relative contributions of the 
various risk factors using odds ratio such as in [52, 57, 58, 114-116]. In the present study 
logistic regression was therefore applied to investigate the relationship between the included 
features and CAN. Such a method revealed the effectiveness of the included features with CAN 
based on odds ratio (OR). 
 Univariate logistic regression was used to assess the individual risk of the included features 
in the development of CAN. Multivariate logistic regression furthermore was applied to 
evaluate the role of the included features in the development of the disease using different 
adjusted sub-sets of features. The outcome of analysis was considered statistically signiﬁcant 
if P-value < 0.05 with 95% conﬁdence interval (CI). The P-value was used to quantify the 
strength of the evidence against the null hypothesis [117]. The confidence interval refers to the 
level of precision of the odds ratio. A large CI indicates a low level of precision of the OR, 
whereas a small CI indicates a higher precision of the OR. All P-values were reported in two-
tailed. All the statistical analyses were based on the following hypotheses: 
  Null hypotheses: ACE I/D polymorphism, EBT, cholesterol blood biochemistry 
features, the demographic data have an insignificant relationship with CAN’s disease. 
 Alternative hypothesis: ACE I/D polymorphism, EBT, cholesterol blood biochemistry 
features, the demographic data have a significant relationship with CAN’s disease. 
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3.5  Performance Analysis 
In this section, the obtained results of the analysis are as follows: 
3.5.1 Participants Characteristics 
This sub-section describes the analysis results of univariate analysis tests to compare the 
differences between the included features in the examined groups as presented in Table 3-6.  
Table 3-6. The characteristics of participants according to the presence of CAN 
Variable Participants with CAN- 
N= 132 (44.15%) 
Participants with CAN+ 
N= 167 (55.85%) 
P value 
Age  61.5 (29-90) 67 (32-87) 0.004 
Waist Circumference  96 (63-130) 96 (165-64) 0.6 
BMI 26.5 (13.3-44.6) 27.2 (15.4-50) 0.2 
LSHR 1.15 (1.01- 1.96) 1.09 (0.87-1.66) 0.000 
DBHR 17.13 (4.5-36) 10.33 (1.8-30.7) 0.000 
VAHR 1.3 (1.1-2.4) 1.1 (0.9-1.7) 0.000 
HGBP 17.5 (0-39) 13 (0-36) 0.000 
LSBP 5.5 (0-29) 8 (0-35) 0.002 
HbA1c  5.7 (5-8) 5.8 (4.8-13) 0.024 
TC  5.1 ± 0.98940 5.1 ± 1.10195 0.9 
Triglyceride  1 (0.2-4.3) 1.2 (0.3-5.47) 0.03 
LDL  3.1 ± 0.97364 3 ± 0.97803 0.5 
HDL  1.4 (0.73-2.9) 1.4 (0.7-3.3) 0.9 
Gender  
 Females 
 Males 
 
 67 (50.8%) 
 65 (49.2%) 
 
 111 (66.5%) 
 56 (33.5%) 
 
0.008 
 
As can be seen in Table 3-6, this study concentrated on 299 participants, 44.15% of these are 
without CAN; and 55.85% are with CAN. Compared to the participants without CAN, the 
participants with CAN are significantly older (P = 0.004). The participants with CAN are 
significantly higher in HbA1c and Triglyceride (P = 0.02) and (P = 0.03) respectively. There 
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is also a significant difference in gender; Females are higher compared to the males (P =0.008). 
The analysis also shows that the participants with CAN are significantly lower in LSHR (P 
=0.000), DBHR (P=0.000), VAHR (P =0.000), and HGBP (P =0.000); but they are 
significantly higher in LSBP (P=0.002). The analysis also demonstrates there are insignificant 
differences recorded in Waist Circumference, BMI, TC, LDL and HDL between the two 
examined groups (P > 0.05).  
Table 3-7. The distribution of ACE polymorphism 
Population (n) DD ID II 
Allele Frequencies 
D  I 
CAN- (132) 32(41%) 66(47.8%) 34(41%) 0.492 0.508 
CAN+(167) 46(59%) 72(52.2%) 49(59%) 0.491 0.509 
Chi-Square (CAN- Vs. CAN+), X-squared = 1.4068, P-value = 0.4 
 
Table 3-7. presents the data for all the polymorphism distribution for both groups using Hardy-
Weinberg equilibrium. As shown, compared to the II and DD polymorphism distribution, the 
distribution of ID polymorphism is higher in both examined groups and higher in CAN+ group 
than CAN- group. It can be seen that both II and DD polymorphism are nearly equal in each 
group, but they are higher in CAN+ group than CAN- group. However, the analysis shows 
there are insignificant differences among the three polymorphism in the assessed groups (P > 
0.05).  
Table 3-8. The distribution of Alleles. 
Alleles D I 
CAN- 130 134 
CAN+ 164 170 
Chi-Square (CAN- Vs. CAN+), X-squared = 0.0012, P-value = 0.9 
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The distribution of Alleles between the two examined groups is presented in Table 3-8. As can 
be observed, the distribution of Allele D is lower than Allele I in both evaluated groups, and 
they are higher in the CAN+ group. Nevertheless, the result of the test also shows there is an 
insignificant difference in the distribution between the examined groups (P > 0.05). 
3.5.2 The Performance of the Included Features with CAN.  
This section presents the evaluation of the association between the included features and CAN 
using various scenarios and sub-sets of features as follows: 
3.5.2.1 The Individual Performance  
 
The individual performances of included features with CAN’s disease are presented in Table 
3-9.  
Table 3-9. The individual performance of included features  
Variable P-Value Odds Ratio 95% CI 
Lower Upper 
Age  0.005 1.03 1.009 1..049 
Gender (Females verses Males) 0.006 1.923 1.203 3.073 
Waist Circumference 0.56 1.005 0.988 1.022 
BMI 0.2 1.032 0.983 1.083 
LSHR 0.000 0.009 0.001 0.085 
DBHR 0.000 0.801 0.758 0.846 
VAHR 0.000 0.001 0.000 0.005 
HGBP 0.000 0.865 0.827 0.905 
LSBP 0.003 1.053 1.018 1089 
HbA1c  0.03 1.443 1.037 2.008 
TC  0.93 1.009 0.812 1.255 
Triglyceride  0.04 1.395 1.013 1.923 
LDL  0.59 0.938 0.742 1.187 
HD  0.86 1.050 0.592 1.863 
ACE Gene II 0.49 Ref.   
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ACE Gene ID 0.32 0.757 0.437 1.313 
ACE Gene DD 0.99 0.997 0.532 1.870 
 
As shown in Table 3-9, any progress in age is significantly associated with the development of 
CAN with (odds=1.03; P= 0.005). Similarly, CAN shows significant increase in females versus 
males with (odds = 1.92; P = 0.006). The prevalence of CAN is related to the high rates of 
HBA1c and Triglyceride with (odds = 1.44; P = 0.03) and (odds = 1.4; P=0.04) respectively. 
As for Ewing battery tests, the analyses show that the increase in LSHR, DBHR, VAHR and 
HGBP significantly contributes to the reduction of the risk of CAN with (odds =0.009; 
P=0.000), (odds =0.801; P=0.000), (odds =0.001; P=0.000) and (odds =0.865; P=0.000) 
respectively. Conversely, the increase in LSBP significantly contributes to the development of 
CAN with (odds=1.053; P=0.003). However, the rest of the included features such as Waist 
Circumference, BMI, TC, LDL, HDL, and ACE gene polymorphism do not show any 
significant association (P > 0.05).  
 
3.5.2.2 The Performance of Cholesterol Blood Biochemistry Features  
 
In this analysis, only cholesterol blood biochemistry features are included as explanatory 
variables while CAN is the dependent variable. The results of the analysis are listed in Table 
3-10.  
Table 3-10. The performance of cholesterol blood features 
Variable P-Value Odds Ratio 95% CI 
Lower Upper 
HbA1c  0.04 1.412 1.001 1.991 
TC  0.3 0.411 0.069 2.488 
Triglyceride  0.07 2.213 0.930 5.265 
LDL  0.3 2.3341 0.397 13.811 
HDL  0.18 3.67 0.529 25.429 
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As presented in Table 3-10, the high rate of HbA1c significantly increases the risk of CAN 
with (odds =1.41; P= 0.04). HbA1c test is a very common and reliable test for diagnosing 
diabetes [118]. This test is used to measure the level of sugar in blood. However, the other 
included features such as TC, Triglyceride, LDL and HDL are insignificant risk factors (P > 
0.05).  
3.5.2.3 The Performance of Demographic Clinical Data  
 
The present analysis evaluated the association of demographic data with CAN. Table 3-11 
illustrates the outcomes of this analysis. 
Table 3-11. The performance of demographic data 
Variable P-Value Odds Ratio 
95% CI 
Lower Upper 
Gender (Females verses Males) 0.01 2.055 1.187 3.561 
Age 0.002 1.033 1.011 1.055 
Waist Circumference 0.8 1.004 0.974 1.035 
BMI 0.3 1.041 0.961 1.128 
 
The outcomes of analysis demonstrate that the occurrence of CAN significantly increases in 
females more than in males with (odds =2.055; P=0.01). The progress in age also significantly 
contributes to the development of CAN’s disease with (odds = 1.033; P= 0.002). However, the 
Waist circumference and BMI features do not show any significant association with CAN’s 
disease (P > 0.05). Gender (females more than males) and progress in age are additional risk 
factors of CAN’s disease [119, 120]. 
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3.5.2.4 The Performance of Ewing Battery Tests  
 
The current analysis involved only EBT as independent variables whereas CAN is the 
dependent variable. The details of the analysis are presented in Table 3-12. 
Table 3-12. The performance of Ewing’s tests 
Variable P-Value Odds Ratio 
95% CI 
Lower Upper 
LSHR 0.01 0.017 0.001 0.372 
DBHR 0.00 0.724 0.659 0.795 
VAHR 0.00 0.02 0.000 0.005 
HGBP 0.000 0.764 0.706 0.827 
LSBP 0.003 1.100 1.033 1.171 
 
The result of analysis demonstrates that all EBT are significantly associated with CAN. This is 
normal because these tests are the traditional tests of diagnosing the disease. The result of 
analysis reveals the increase in LSHR, DBHR, VAHR and HGBP contributes significantly to 
reducing CAN with (odds = 0.017; P= 0.000), (odds= 0.724; P=0.000), (odds = 0.02; P= 0.000) 
and (odds = 0.764; P = 0.000) respectively. However, the increase in LSBP significantly 
contributes to the development of CAN with (odds = 1.1; P = 0.003).  
3.5.2.5 The Performance of ACE I/D Polymorphism  
 
In the current analysis, only ACE I/D polymorphism is included with changes in 
polymorphism. The performance of ACE I/D polymorphism is explained in Table 3-13.  As 
can be observed from the analysis, ACE I/D polymorphism does not show any significant 
association with CAN’s disease.  
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Table 3-13. ACE I/D polymorphism performance 
Variable P-Value Odds Ratio 
95% CI 
Lower Upper 
ACE Gene II 0.49 Ref.   
ACE Gene ID 0.32 0.757 0.437 1.313 
ACE Gene DD 0.99 0.997 0.532 1.870 
ACE Gene ID 0.49 Ref.   
ACE Gene II 0.32 1.32 0.762 2.3 
ACE Gene DD 0.33 1.32 0.752 2.31 
ACE Gene DD 0.49 Ref.   
ACE Gene II 0.9 1.0026 0.5348 1.88 
ACE Gene ID 0.33 0.8 0.4 1.3 
 
 
3.5.2.6 The Performance of All Features  
 
The final analysis involved all features as independent variables and CAN as the dependent 
variable. The details of the analysis are presented in Table 3-14. 
Table 3-14. The performance of all included features 
Variable P-Value Odds Ratio 
95% CI 
Lower Upper 
Gender (Males verses Female) 0.3 0.640 0.246 1.662 
Age 0.6 0.992 0.956 1.029 
Waist Circumference 0.8 1.004 0.957 1.054 
BMI 0.6 1.034 0.911 1.174 
LSHR 0.01 0.017 0.001 0.400 
DBHR 0.000 0.696 0.623 0.779 
VAHR 0.000 0.018 0.000 0.006 
HGBP 0.000 0.747 0.680 0.821 
LSBP 0.003 1.106 1.034 1.183 
HbA1c  0.8 1.106 0.577 1.940 
TC  0.6 0.492 0.031 7.844 
Triglyceride  0.3 2.040 0.511 8.140 
LDL  0.6 2.178 0.133 35.581 
 52 
 
HDL  0.3 4.766 0.244 92.899 
ACE Genotype II 0.4 Ref.   
ACE Genotype ID 0.3 1.811 0.593 5.529 
ACE Genotype DD 0.96 1.030 0.343 3.095 
 
As presented in Table 3-14, EBT show a significant association with CAN (P < 0.05). The 
result reveals that the increase in LSBP significantly contributes to the risk of CAN with (odds 
=1.106; P=0.003). Conversely, the increase in LSHR, DBHR, VAHR, HGBP is significantly 
associated with a reduction in the likelihood of exhibiting CAN with (odds =0.017; P=0.01), 
(odds =0.696; P=0.000), (odds =0.02; P=0.000) and (odds = 0.747; P=0.000) respectively. 
However, the rest of the included features statistically are ineffective risk factors (P > 0.05). 
This might be due to the super performance of EBT that covers the risk of the other included 
features in this adjusted set of features.  
 
3.6  Chapter Summary  
In this chapter, the correlation between Angiotensin Converting Enzyme Gene (ACE) I/D 
polymorphism, cholesterol blood biochemistry features, demographic data and CAN using 
statistical analysis methods is investigated. Univariate statistical analysis is used to describe 
the difference in distribution between the patients and the healthy. Logistic regression 
(univariate and Multivariate) is also applied to determine the risk of the included features in 
this study. Numerous adjusted sub-sets are developed based on their background and evaluate 
their risk in the same way. The outcomes of this study show there is an insignificant association 
between ACE gene polymorphism and CAN’s disease.  
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Chapter 4: The Risk of Family History of Diabetes and 
Ewing’s Tests on the Prevalence of Diabetes Mellitus 
This chapter analyzes the risk of family history and Ewing Tests factors on the prevalence of 
diabetes mellitus (DM). In particular, we focus on how Ewing’s tests and different family 
history factor are correlated with the prevalence of diabetes mellitus (DM). We use a cross-
sectional study to examine the role of family history, Ewing’s tests combined with various 
clinical tests on the incidence of diabetes mellitus (DM).  
4.1  Introduction  
Diabetes Mellitus (DM) is a number of metabolic diseases that occur due to the weakness in 
insulin-production [121]. This disease is one of the most prevalent non-contagious diseases 
worldwide [122]. The number of people with diabetes is rapidly increasing. Recent statistics, 
for example, have shown there are nearly 415 million patients with (DM), their number is likely 
to rise to 642 million patients by 2040 [123].  Moreover, about 1.7 million Australians are 
suffering from diabetes; their number is anticipated to be 3 million by 2025 [124, 125]. In 
comparison to other chronic diseases such as CVD and cancer, DM  has faster prevalence’s 
rate among Australian people [126]. The rate of mortality by DM  is two and four times higher 
in remote and very remote areas, respectively than in the major cities of Australia [127]. 
Diabetes is a complex disease influenced by multi-factors like genetics, lifestyle and 
environmental conditions [128-131]. The familial aggregation of diabetes furthermore 
attributed to the collective action of genetic and environmental factors that shared among 
family members such as dietary habits and lifestyle [132].  Family history is considered one of 
the most genetic risk factors that significantly contribute to the prevalence of the disease. This 
factor refers to the health information of the patient’s relatives such as parents, children, and 
siblings about a specific disease. The family history of disease provides a prior view of the 
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disease within the family; it also facilitates the analysis of familial patterns. The family history 
provides a valuable and low-cost tool that can be used to evaluate the risk of multifactorial 
diseases [133]. Predominantly, people with a definite family history of the disease are more 
likely to develop the disease [134]. The risk of family history has been widely assessed with 
various diseases such as hypertension [116], certain cancers [135], Alzheimer’s disease [136] 
and stroke [137]. It also provides information about the risk of rarer conditions resulting from 
mutations in a single gene such as Sickle-cell disease (SCD)[138].  
Many cross-sectional studies in the literature have provided information on the risk of 
a family history of diabetes for the development of the disease such as [57-60, 62-66, 139]. The 
effect of family history is still controversial and demands more details for better understanding 
[133]. Despite recent advances in understanding the human genome, there are still inadequacies 
in the existing epidemiological approaches to assess the influence of genetic factors on chronic 
diseases such as diabetes [140]. There is, also, a necessity to assess the prevalence of the disease 
in various regions and developing valuable health strategies [57, 141].  
Analyzing health data collected for patients with diabetes using statistical analysis 
methods importantly helps to discover underlying patterns and trends for the patients. Thus, it 
significantly reduces the disease complication such as CAN. In this chapter, a cross-sectional 
study is provided to evaluate the risk of family history combined with EBT and other clinical 
tests for the prevalence of DM. In particular, this study focuses on participants from rural 
Australia.  
This chapter is structured as follows: Section 4.2 describes the problem. The 
methodology is presented in Section 4.3. The results are discussed in Section 4.4. Finally, the 
chapter summary is presented in Section 4.5. 
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4.2  Problem Overview 
Family history (FH) has been shown as a significant risk factor for several diseases including 
diabetes mellitus (DM). A large number of cross-sectional studies demonstrated that a positive 
family history of diabetes and other risk factors are independent risk factors for diabetes. 
 For example, Zhang, et al. [57] in their study revealed that people with a positive family 
history of diabetes are more likely to develop the disease than those without a family history 
with (odds = 6.16; P < 0.05). A different study by [59] concluded that the odds ratio of patients 
with a positive family history of diabetes is higher than patients without a family history with 
(odds = 1.53; P <0.05). Du, et al. [58] also demonstrated that patients with a positive family 
history of diabetes are at higher risk than patients with negative family history with (odds = 
1.69; P <0.05). Another cross-sectional study in [60] proved that patients with a positive history 
are at higher risk for developing the disease with (odds = 7.302; P = 0.003). Other studies in 
[62] and [63] have also revealed that positive family history of diabetes is correlated with the 
prevalence of the disease with (odds = 3.35, P = 0.05) and (odds = 2.3; P = 0.000) respectively. 
A previous cross-sectional study in [139] also discovered that positive family history increases 
the risk of diabetes with (odds = 5.5, P = 0.05).  
The above outcomes of the association between the risk of positive family history and the 
prevalence of diabetes, however, were obtained from different populations in different 
countries such as USA, China, Japan, Korea, and India. The risk of genetic factors such as 
family history for the prevalence of diabetes is varied among different ethnicities [142, 143].  
In Australia, there were two previous cross-sectional studies conducted to show the risk of 
a family history of diabetes for the prevalence of the disease [65, 66]. They used data from the 
Blue Mountain Eye Study and the Australian Diabetes, Obesity, and Lifestyle Study 
(AusDiab). The findings of studies revealed that the presence of family history significantly 
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contributed to the development of diabetes with (odds = 1.82; P <0.05) and (odds = 1.7; P 
<0.05).  
Although the studies in [65, 66] investigated the effect of family history on the prevalence 
of diabetes among the Australian population, these studies did not investigate the risk of Ewing’ 
tests on diabetes prevalence. To the best knowledge of this researcher, Ewing tests have not 
been used before to investigate the prediction of diabetes mellitus (DM). In the present chapter, 
an in-depth analysis of the association among the family history risk categories of diabetes and 
Ewing battery tests, and prevalence of diabetes was carried out using different data from 
DiScRi.  
4.3  Methodology  
This section presents the main steps taken in the present study as shown in Figure 4-1.  
 
Figure 4-1. Depicts the framework of the present study 
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4.3.1 Dataset and Features Extraction  
To conduct this study, a real dataset from the diabetes complications screening research 
initiative project (DiScRi) was used. The DiScRi was organized at Charles Sturt University in 
Australia [35]. The data were collected and analyzed according to the policies of the Ethics in 
Human Research Committee (HRECs) of the university. This dataset contains a 
comprehensive collection of diagnostic tests (more than 200 tests) related to CAN. This 
present study included only demographic data, cholesterol blood biochemistry tests and Ewing 
battery tests (EBT) as listed in Tables 4-1 to 4-3 respectively. Covariates were adjusted into 
four subsets based on their types. In the first subset, the analysis was adjusted only for 
demographic data. In the second subset, the investigation was only of EBT. The cholesterol 
blood biochemistry tests were adopted in the third subset whereas the fourth set involved all 
covariates. Based on the availability of family history information only 600 participants were 
involved in the present study. 
Table 4-1. The demographic and clinical data 
Variable Description 
Gender Male / Female 
Age  No. of years 
Waist circumference Excess fat around the waist 
BMI Body Mass Index 
The family history of Diabetes (Yes / No) either parent as well as grandparents etc, 
Hypertension status  (Yes/No) 
Diabetes Status  (Yes/No) 
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Table 4-2. The cholesterol blood biochemistry features 
Variable Description 
HDL  High-density lipoprotein measured in (mmol/L) 
LDL  Low-density lipoprotein measured in (mmol/L) 
TC  Total cholesterol measured in (mmol/L) 
Triglyceride  Level of triglyceride in the blood measured in (mmol/L) 
TC/HDL ratio The ratio of total cholesterol to high-density lipoprotein measured 
in (mmol/L) 
HbA1c  (glycated hemoglobin) quantifies the level of sugar in the blood 
over time measured in (mmol/L) 
Screening glucose Level of glucose in the blood over time measured in (mmol/L); 
also called Glucose Tolerance Test (GTT) 
Glucose  Also called fasting glucose test (FGT); the quantity of glucose in 
blood measured in (mmol/L)  
 
Table 4-3. Ewing Battery Tests 
Variable Description 
LSHR Lying to Standing Heart Rate change 
DBHR Deep Breathing Heart Rate change 
VAHR Valsalvamanoeuvre Heart Rate change 
HGBP Hand Grip Blood Pressure change 
LSBP Lying to Standing Blood Pressure change 
 
4.3.2 Univariate Analysis and Regression Methods  
Statistical analysis is a significant field of data mining. It has been extensively employed in 
discovering knowledge from collected data. Applying such analyses to medical studies has 
shown essential consequences such as discovering new risk factors, the prevalence of diseases 
and survivability. A number of statistical tests and regression methods have therefore been 
carried out in line with the objectives of this study, as listed in Table 4-1. All statistical analyses 
were applied using SPSS version 20.0 (SPSS, Inc., Chicago, IL, USA) and R language. 
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Table 4-4. Statistical Analysis Tests 
Test Type Variables  
Wilcoxon-Mann- Whitney Test 
Age, Waist Circumference, BMI, DBHR, VAHR, 
HGBP, LSBP, LSHR, SLHR, HbA1c, Triglyceride, 
HDL, TC/HDL ratio, FGT, GTT, TC, LDL. 
Shapiro–Wilk W-test All Continuous features. 
Chi square Test Gender, Diabetes Status, HT Status. 
Logistic Regression All covariates. 
 
4.3.3 Univariate Analysis 
This study used several univariate analysis tests to evaluate the differences between the studied 
groups. For example, the Shapiro-Wilk test was conducted to assess the normality of 
continuous features. Due to the non-normal distribution of the covariates, Wilcoxon-Mann- 
Whitney test was used with the continuous skewed features (expressed as median, range). Chi-
Square test was employed in analyzing the categorical features (expressed as number and 
percentage). 
4.3.3.1 Regression Methods 
The present study used logistic regression to measure the risk of the included features for the 
prevalence of diabetes.  As stated previously in chapter 3, logistic regression represents one 
of the most common regression methods used for analyzing a dataset. This method has been 
widely involved in medical studies to determine the association between various features and 
diseases such as [57, 58, 144, 145].  One of the advantages of using logistic regression is the 
odds ratio (OR).  In the present study, logistic regression has  been applied to estimate the 
association between diabetes disease and the covariates based on the obtained odds ratios.  
Univariate logistic regression is used to determine the individual risk of the covariates with 
diabetes prevalence. Meanwhile, multivariate logistic regression was employed to assess the 
risk of covariates using different adjusted subsets of features. The P-value was adapted to 
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quantify the statistical significance of the analysis. The results of the analysis are considered 
statistically signiﬁcant if P-value < 0.05 with 95% conﬁdence interval (CI) which estimates 
the precision of the odds ratio. All P-values were in reported for two-tailed. All analyses were 
proposed based on the following hypotheses: 
 Alternative hypothesis: Family history, EBT, Cholesterol Blood Biochemistry 
features, and Clinical data are significantly associated with diabetes prevalence  
 Null hypotheses: Family history, EBT, Cholesterol Blood Biochemistry features, and 
Clinical data are insignificantly associated with diabetes prevalence. 
4.4  Performance Analysis  
This section describes the evaluation of the analysis as follows:  
4.4.1 The Characteristics of the Participants 
In this sub-section, the dissimilarities of the included features of the participants based on the 
presence and absence of family history are explained. The differences between the included 
features for the participants are presented in Table 4-5. 
Table 4-5. The characteristics of the covariates 
Variable Participants without FH  
N= 259 (43.2%) 
Participants with FH  
N= 341 (56.8%) 
P value 
Age 70 (29-86) 67 (33-90) 0.000 
Diabetes Status 
 Yes 
 No 
 
 45 (17.4%) 
 214 (82.6%) 
 
 204 (59.8%) 
 137 (40.2%) 
0.000 
HT Status 
 Yes 
 No 
 
 160 (61.8%) 
 99 (38.2%) 
 
 261(76.5%) 
 80 (23.5%) 
0.000 
Gender 
 Male  
 Female  
 
 132 (50.1%) 
 127 (49.9%) 
 
 155 (45.5%) 
 186 (55.5%) 
0.1 
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Waist Circumference 97 (63-165) 101 (68-125) 0.000 
BMI 26.56 (15.41-50) 28.08 (13.34-40.12) 0.000 
DBHR 12.86 (1.8-34.72) 14 (2.43-36) 0.01 
LSHR 1.12 (0.91-1.96) 1.12 (0.87-1.84) 0.9 
VAHR 1.23 (0.94-1.66) 1.2 (0.91-2.35) 0.1 
LSBP 9 (0-34) 7 (0-35) 0.6 
HGBP 16.26 (0-33) 16.65 (0-38) 0.001 
HbA1c 5.8 (4.8-8.2) 6.3 (5.2-13) 0.000 
Triglyceride 1.4 (0.2-5.01) 1.3 (0.26-5.47) 0.7 
TC 5 (2.5-8) 4.5 (2.7-8.1) 0.000 
HDL 1.3 (0.7-3.3) 1.28 (0.72-2.9) 0.3 
LDL 2.94 (0.8-5.5) 2.5 (0.95-5.59) 0.0000 
TC/HDL ratio 3.7 (1.6-7.4) 3.5 (1.4-7.4) 0.007 
FGT 5.4 (3.5-16.6) 6.4 (3.3 -17.3) 0.000 
GTT 5.3 (2.3-16.5) 6.3 (3.2-16.4) 0.000 
 
As evident from Table 4-5, the present study focused on 600 participants, 43.2 % of whom are 
with negative family history whereas 56.8% are with positive family history. Compared to the 
participants with negative family history, the participants with positive family history 
significantly tend to be younger (P < 0.05). The prevalence of diabetes disease is significantly 
higher among the participants with positive family history (P < 0.05). There is also a substantial 
difference in the incidence of hypertension disease; the participants with positive family history 
are higher (P < 0.05). The anthropometric measurements such as waist circumference and BMI 
are also higher (P < 0.05). The analysis also reveals significant differences in some of the EBT 
such as DBHR and HGBP. These tests are significantly higher among participants with a family 
history than those without a family history (P < 0.05). The rates of major diabetes tests such as 
HbA1c, FGT, and GTT are significantly higher (P<0.05). The result of univariate analysis also 
demonstrates that the cholesterol blood biochemistry features such as TC/HDL ratio, LDL, and 
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TC are significantly lower (P < 0.05). However, there is insignificant difference between the 
examined groups based on gender, LSHR, VAHR, LSBP, Triglyceride, and HDL. 
4.4.2 The Risk of Covariates 
This section explores the role of the covariates in developing DM using different adjusted 
subsets of features as follows:  
4.4.2.1 The Individual Performance of the Covariates 
Table 4-6 presents the individual risk of the covariates for the prevalence of diabetes mellitus 
(DM).  
Table 4-6. The individual risk of the covariates 
Variable 
P-Value Odds Ratio 95% CI 
Lower Upper 
FHDM (Yes versus No) 0.000 7.081 4.806 10.433 
Gender (Males versus Females)  0.001 0.572 0.412 0.795 
HT Status (Yes versus No) 0.000 5.385 3.481 8.330 
Age 0.5 1.005 0.990 1.020 
Waist Circumference 0.000 1.033 1.019 1.048 
BMI 0.000 1.112 1.067 1.159 
LSHR 0.05 0.223 0.050 1.000 
DBHR 0.1 1.016 0.993 1.040 
VAHR 0.005 0.201 0.065 0.622 
HGBP 0.000 0.926 0.9 0.952 
LSBP 0.031 1.025 1.002 1.048 
HbA1c  0.000 10.912 7.408 16.075 
Triglyceride  0.8 0.976 0.79 1.205 
TC  0.000 0.376 0.302 0.469 
HDL  0.04 0.606 0.375 0.979 
LDL 0.000 1.11 0.870 1.012 
TC/HDL ratio 0.000 0.547 0.453 0.661 
FGT 0.000 3.075 2.534 3.731 
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GTT 0.000 1.759 1.545 2.003 
 
As presented in Table 4-6, the presence of family history of diabetes significantly contributes 
to the development of diabetes with (odds = 7.081; P = 0.000). Gender is also a risk factor; 
with males less likely to develop diabetes than females with (odds= 0.572; P =0.001). The 
results also show that the presence of hypertension disease significantly increases the 
possibility of diabetes with (odds = 5.385; P = 0.000). The increase in waist circumference or 
BMI is significantly associated with the prevalence of diabetes with (odds = 1.033; P = 0.000) 
and (odds = 1.112; P = 0.000) respectively. The high rates of LSHR, VAHR and HGBP greatly 
contribute to the reduction of the risk of diabetes with (odds = 0.2233; P=0.05) (odds=0.201; 
P=0.005) and (odds = 0.926; P=0.000) respectively; 
 On the other hand the increase in LSBP play an important role in diabetes’s incidence with 
(odds =1.025; P=0.03). However, the DBHR test shows insignificant association with the 
diabetes (P > 0.05). The results also showed that the increases in HbA1c, FGT and GTT 
effectively develop the disease with (odds= 10.912; P = 0.000), (odds = 3.075; P = 0.000) and 
(odds = 1.759; P =0.000) respectively. The rise in LDL test significantly collaborated in the 
progress of diabetes with (odds = 1.11; P = 0.000). In contrast, the analysis discloses that the 
rise in TC and HDL and TC\HDL ratio tests significantly reduce the risk of the disease with 
(odds = 0.376; P=0.000) (odds = 0.606; P=0.04) and (odds = 0.547; P =0.000) respectively. 
The rest of the covariates such as age, and triglyceride however show insignificant influence 
on diabetes development. 
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4.4.2.2 The Performance of Ewing Battery Tests Subset 
The present analysis evaluated the risk of EBT in the development of diabetes disease as 
presented in Table 4-7.  
Table 4-7. The risk of Ewing battery tests 
Variable  P-Value Odds Ratio 
95% CI 
Lower Upper 
LSHR 0.3 0.483 0.101 2.314 
DBHR 0.005 1.038 1.011 1.066 
VAHR 0.01 0.216 0.065 0.718 
HGBP 0.000 0.922 0.896 0.949 
LSBP 0.002 1.041 1.015 1.067 
 
As apparent in Table 4-7, the result of the analysis indicates that any increase in DBHR and 
LSBP tests significantly contributes to the occurrence of diabetes with (odds=1.038; P =0.005) 
(odds = 1.041; P=0.002) respectively. Conversely, the increase in VAHR and HGBP tests 
significantly reduces the risk of disease with (odds = 0.216; P = 0.012) (odds= 0.922; P =0.000) 
respectively. The change in the value of LSHR test, however, shows an insignificant 
association with the disease.  
4.4.2.3 The Performance of Demographic Data Subset 
The present analysis was conducted to assess the risk of demographic data for the prevalence 
of diabetes as shown in Table 4-8.  
Table 4-8. The risk of demographic data  
Variable  P-Value Odds Ratio 
95% CI 
Lower Upper 
FHDM (Yes verses No) 0.000 7.61 4.9 11.81 
Gender ( Males verses Females) 0.000 0.304 0.19 0.486 
Age 0.1 1.017 0.993 1.041 
HT Status (Yes verses No) 0.000 4.68 2.736 7.997 
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Waist Circumference 0.05 1.027 0.999 1.055 
BMI 0.1 1.051 0.974 1.135 
 
According to the results of the analysis as presented in Table 4-8,participants with a 
positive family history of diabetes are at higher risk than participants with a negative family 
history of acquiring diabetes with (odds = 7.61; P = 0.000). The presence of hypertension 
disease also shows a significant contribution to the development of diabetes with (odds = 4.68; 
P = 0.000). Gender also plays a significant role in the incidence of the disease; males are less 
likely than females with (odds = 0.304; P=0.000). The increase in waist circumference 
significantly contributes to the disease prevalence with (odds= 1.027; P=0.05). Age and BMI, 
however, show insignificant association with the disease. 
4.4.2.4 The Performance of Cholesterol Blood Biochemistry Subset 
The risk of cholesterol blood biochemistry features for the prevalence of diabetes is presented 
in this analysis as listed in Table 4-9.  
Table 4-9. The risk of cholesterol blood biochemistry subset 
Variable 
 
P-Value Odds Ratio 
95% CI 
Lower Upper 
HbA1c  0.000 4.495 2.849 7.094 
Triglyceride  0.2 0.758 0.501 1.146 
TC  0.2 0.643 0.346 1.194 
HDL  0.6 0.735 0.242 2.230 
LDL  0.8 0.918 0.487 1.731 
TC/HDL ratio 0.010 0.568 0.368 0.875 
FGT 0.000 1.935 1.523 2.458 
GTT 0.000 1.344 1.173 1.541 
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The result of analysis conducted shows that the high rates of HbA1c, FGT and GTT greatly 
contribute to the development of the disease with (odds = 4.495; P = 0.000), (odds = 1.935; P 
= 0.000), (odds = 1.344; P = 0.000) respectively. In contrast, the increase in TC/HDL ratio 
plays a significant role in decreasing the prevalence of diabetes with (odds = 0.568; P = 0.010). 
The rest of the included features in the present subset like Triglyceride, TC, HDL and HDL, 
however, show an insignificant influence 
4.4.2.5The Performance of All Covariates. 
The present analysis evaluated the risk of all interesting features as independent variables and 
diabetes status as the dependent variable as presented in Table 4-10.  
Table 4-10. The performance of all Covariates 
Variable P-Value Odds Ratio 
95% CI 
Lower Upper 
FHDM( Yes Vs No) 0.000 3.911 2.088 7.322 
Gender( Males Vs Females) 0.000 0.181 0.082 0.399 
Age 0.3 1.017 0.979 1.056 
Waist Circumference 0.2 1.030 0.984 1.079 
BMI 0.3 1.060 0.945 1.188 
LSHR 0.3 3.921 0.225 68.256 
DBHR 0.000 1.115 1.060 1.174 
VAHR 0.1 0.180 0.022 1.503 
HGBP 0.1 0.962 0.912 1.014 
LSBP 0.000 1.088 1.042 1.136 
HbA1c 0.000 4.434 2.482 7.922 
Triglyceride 0.6 0.885 0.541 1.447 
FGT 0.000 1.881 1.429 2.475 
GTT 0.002 1.279 1.097 1.491 
HT Status ( Yes Vs No) 0.008 3.217 1.360 7.606 
TC 0.1 0.561 0.274 1.146 
HDL 0.6 0.739 0.211 2.591 
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LDL 0.3 0.693 0.332 1.447 
TC / HDL ratio 0.003 0.477 0.291 0.780 
 
As can be seen in Table 4-10, the analysis demonstrates that the odds ratio of diabetes is 
significantly associated with the presence of a family history of diabetes with (odds = 3.911; P 
= 0.000). Participants with positive hypertension are more likely to acquire diabetes with (odds 
= 3.217; P = 0.008). Hypertension is considered one of the top three cardiometabolic risk 
factors of diabetes [146]. The increase in rates of HbA1c, FGT, and GTT significantly 
contribute to the incidence of disease with (odds = 4.434; P = 0.000), (odds = 1.881; P = 0.000) 
and (odds = 1.279; P = 0.002) respectively. HbA1c , FGT and GTT are standard diabetes tests 
recommended by the American Diabetes Association [147]. The increase in EBT such as 
DBHR and LSBP also contributes significantly to the prevalence of disease with (odds= 1.115; 
P= 0.001) (odds= 1.088; P=0.001) respectively. These tests play a role in increasing the heart 
rate and blood pressure that contributes to the development of diabetes. There is a significant 
correlation between gender and the disease; males are less likely to acquire the disease with 
(odds = 0.181; P= 0.000). The hormones of women are more likely to change than men due to 
reproductive and obesity factors during a lifetime [148]. In contrast, the increase in TC/HDL 
ratio significantly contributes to the reduction of the disease’s occurrence with (odds= 0.477; 
P =0.003). There is however an insignificant association between diabetes and the rest of the 
covariates. 
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Figure 4-2. Depicts the risk of FH in different populations 
The risk of a family history of diabetes reported in various studies in the literature is presented 
in Figure 4-2. The outcomes of the current study clearly show that positive family history 
significantly increases the risk of diabetes prevalence with (odds = 3.911; P = 0.000). In the 
present study, participants with a family history were found to be four times more likely to 
develop the disease than those participants with a negative history. Thus, it is not surprising 
that the prevalence of diabetes increases among those with a family history of this disease. In 
comparison with the existing studies, it was observed that the risk of family history in the 
current study is very close to the risk of the study among the Sri Lankan population [62]. The 
risk of the current study, however, is higher compared to risks reported in previous studies that 
conducted among the rural population in Australia [65, 66]. This could be attributed to the 
effect of lifestyle and public awareness. Furthermore, in the present study different subsets of 
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features were evaluated. The obtained risks from the USA, Korean and Chinese populations 
were however much higher than those of this current study [57, 60, 139]. It is known that the 
effect of family history differs among different populations.  
4.5  Chapter Summary 
This chapter presented a cross-sectional study that evaluated the risk of family history for 
developing diabetes mellitus. Ewing’s tests and other clinical tests were conducted to determine 
the prevalence of diabetes mellitus (DM) among Australia's rural population. About 600 
participants were involved in the study. Logistic regression was implemented to assess the risk 
of the covariates based on different adjusted subsets. The results of the study showed that 
family history of diabetes is significantly associated with the prevalence of the disease with 
(odds= 3.911; P = 0.000). Ewing tests such as DBHR and LSBP were significant indicators 
with (odds= 1.115; P= 0.001) (odds= 1.088; P=0.001). Family history, thus, could be exploited 
as a facilitating tool for genomic studies. Ewing tests such as DBHR and LSBP are also risk 
factors in developing diabetes and should be considered. 
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Chapter 5: Improving Predictive Accuracy of Cardiac Autonomic 
Neuropathy Disease Using Heart Rate Variability Features 
This chapter addresses a significant challenge, which is how to improve the prediction accuracy 
of CAN disease with some missing Ewing’s tests.  This study developed a predictive model 
based on heart rate variability methods to enhance the predictive accuracy of CAN disease. The 
study also evaluated the model using DiScRi dataset and compared it with the existing model. 
5.1 Introduction 
Cardiovascular autonomic neuropathy (CAN) is a common but seemingly forgotten and 
underdiagnosed form of diabetes complications [149]. This disease damages the cardiac nerve 
fibers, which innervate the heart muscle and blood vessels [90]. Due to the high correlation 
between diabetes and CAN, the number of patients with CAN continues to increase. For 
instance, the percentage of Australians with diabetes has increased from 4.5% in 2011-12 to 
5.1% in 2014-15 [150]. Furthermore, about 20% to 73% of patients with diabetes Type 2 and 
17% to 90% of patients with diabetes Type 1 are at high risk of developing CAN [151, 152]. 
Though CAN is a common complication, the significance of CAN has not been fully estimated 
as well as there are no unified therapy algorithms so far [153]. 
Ewing battery tests (EBT) are the conventional tests of predicting CAN. Despite the 
efficient performance of these tests, EBT are however not conclusive or definitive tests [154, 
155]. Besides, performing all the five conventional tests for all patients is often not possible 
due to mobility and breathing challenges. Thus, relying on these tests in predicting the disease 
sometimes poses the challenge of an incomplete set of EBT. The availability of other tests such 
as ambulatory blood pressure monitoring, and heart rate variability (HRV), provides additional 
tests that can help in diagnosing CAN’s disease [156].  
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Many models in the literature have proposed to predict the disease using EBT combined 
with various tests [7, 67-72]. These models, however, do not investigate the contribution of 
HRV methods in enhancing the predictive accuracy of CAN, especially with incomplete EBT. 
It is therefore essential to understand the disease and identify the signs and symptoms to 
provide appropriate treatment [157]. Discovering new risk factors and constructing a useful 
predictive model would undoubtedly provide a significant and valuable contribution to 
reducing the prevalence of the disease. 
Using machine-learning algorithms to extract knowledge from data in prediction tasks 
has been proven in various fields. For example, the development of machine learning 
algorithms to assess and analyze medical data collected from patients with diabetes for 
diagnosis of CAN has been reported [158, 159]. In this chapter, the aim is to include the 
advantages of HRV analysis methods in the clinical evaluation of CAN, specifically in situations 
of incomplete EBT. Therefore, the study proposed a predictive model to predict CAN using 
EBT combined with HRV methods. The recommended model investigates some machine 
learning methods, which are commonly used in prediction. The contributions of the work 
described in this chapter are: 
 Identification of the essential methods of HRV that could improve the prediction of CAN 
using mean decrease accuracy (MDA) implemented in random forest. 
 Building of a predictive model capable of predicting CAN with an incomplete set of 
EBT.  
 Validating the predictive model by comparing it with recent methods. 
The rest of this chapter comprises the following: Section 5.2 describes the problem and 
motivation. A brief introduction to the HRV analysis methods with their significance is 
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provided in Section 5.3. Section 5.4 explains the framework of the predictive model, while 
Section 5.5 discussed the outcomes. The chapter summary is presented in Section 5.6.  
5.2  Problem Description 
Despite the excellent performance of Ewing tests in predicting CAN, these tests, however, are 
still inconclusive and not a gold standard in predicting the disease. The criteria and staging for 
diagnosing the disease also remain obscure [44]. Furthermore, to fulfill all EBT for all patients 
is often impossible. For example, due to the inherent insensitivity of patients, these tests are 
inappropriate for aged patients and patients with comorbidities diseases [158]. Ewing tests are 
also complicated and require time to carry out [11]. Mobility and breathing difficulties also 
prevent the full achievement of these tests. For example, some patients are incapable of 
performing the lying to stand test [7] or the Valsalva maneuver test [11]. This indicates that 
further tests should be explored to build a new predictive model which enhances the prediction 
of CAN.  
Several studies in the literature have investigated the contribution of various tests in 
improving CAN’s disease prediction. For example, the work in [7] proposed Automated 
Iterative Multitier Ensemble (AIME) to diagnose CAN’s disease using blood biochemistry 
features and the EBT. Another work by Kelarev, et al. [70] introduced ensembles classifiers 
based on Ripple down Rules to detect CAN’s disease included only EBT. Different work by 
[68] also proposed to improve the classification of the disease by combining EBT with 
additional tests along with clinical data such as age, sex, diabetes status, blood pressure (BP), 
body-mass index (BMI), blood glucose level (BGL), and cholesterol profile. The work in [71] 
also proposed many ensembles classifiers based on decision trees classifiers using EBT and 
ECG features.  
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However, these models do not use heart rate variability (HRV) methods. The only study 
that examined the contribution of heart rate variability (HRV) methods was by [74]. This study 
suggested an iterative Multi-Layer Attributes Selection and Classification (MLASC) model. 
The MLASC model, however, does not explore the essential HRV methods that could enhance 
the predictive accuracy of CAN and failed to handle the issue of incomplete EBT. 
5.3  Heart Rate Variability  
Heart Rate Variability (HRV) is a variation in interval times between two adjacent heartbeats, 
as explained in Figure 5-1 [160-162]. It is an analysis method used to assess the regulation of 
cardiac autonomic by calculating the sinus rhythm variability [163]. The sinus rhythm time 
series is derived from the RR interval sequence (interval between two adjacent heartbeats) by 
extracting only NN interval (normal sinus to normal sinus inter-beat interval).  
  
Figure 5-1. HRV signal 
5.3.1 Classifications of HRV Methods 
In general, heart rate variability (HRV) is calculated using different analysis methods. The most 
commonly employed methods are linear, and non-linear [164]. For more details, an exhaustive 
explanation of various HRV methods, their meanings, and clinical use kindly refer to references 
[165, 166]. 
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5.3.1.1 Linear Analysis Methods  
Linear analysis methods are classified into time domain analysis methods and frequency 
domain analysis methods.  
5.3.1.1.1 Time Domain Analysis Methods 
Time domain analysis methods are parameters used to calculate the changes in signals over 
time. These methods deal with a sequence of NN intervals as an unordered set of intervals and 
apply different techniques among the intervals. The most common parameters of time domain 
analysis methods are : 
 Standard Deviation of NN intervals (SDNN). 
 Number of pairs of successive NNs that differ by more than 50 ms (NN50 (%)).  
 The proportion of NN50 divided by total number of NNs (pNN50%). 
 The standard deviation of successive differences (SDSD).  
 Root mean square of successive differences (RMSSD). 
 Geometrical methods such as the triangular interpolation of NN interval histogram 
(TINN), poincare geometry (Poincare plot). 
5.3.1.1.2 Frequency Domain Analysis Methods  
The frequency domain methods (also called spectral analysis) are used to measure the 
distribution of signal’s energy over a range of frequencies. These methods assign bands of 
frequencies then count the number of matched NN intervals in each band. The measured bands 
could be high frequency (HF), low frequency (LF), very low frequency (VLF) and ultra-low 
frequency band (ULF). Total power (TP) represents the sum of the four spectral bands. The 
measurements are expressed in the absolute value of power (ms2) and normalized units (n.u.).  
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5.3.1.2 Nonlinear Analysis Methods  
The non-linear methods aim to quantify the structure and complexity of RR interval based on 
the chaos theory and fractal geometry. Unlike linear methods, non-linear methods are not 
affected by non-stationarity. They include Approximate Entropy, Power Law Exponent, 
SampEn, ShanEn and Detrended Fluctuation Analysis. 
5.3.2 The Significance of HRV Methods 
Heart rate variability (HRV) analysis methods form practical tools that have shown super 
proficiency in detecting various diseases and daily life activities. HRV methods are considered 
noninvasive and objective methods used in assessing the autonomic nervous system (ANS) 
[167]. The ANS controls several tasks the in the human body, such as the rate of breathing 
[168] and blood pressure [169], as presented in Figure 5-2 from [170]. 
 
Figure 5- 2. The Autonomic Nervous System (ANS)  
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 HRV methods are also robust tools employed in cardiology detection [163]. They have shown 
an opposite association with multi diseases such as diabetes mellitus, hypertension, and 
metabolic syndrome [171]. Using these methods plays an important role in revealing 
congestive heart failure [172], post-cardiac transplant [173], depression [174]. HRV methods 
have been used to detect the sudden death syndrome among infants, and reduced survival in 
premature babies [175]. They have been proven to be independent factors for mortality after 
acute myocardial infarction [176]. Using HRV methods in monitoring the human body is more 
accurate and efficient than the traditional heart measures [163]. They have already been used 
in identifying neonatal sepsis [177] and arrhythmia risk [178]. 
 The HRV analysis methods have also widely examined the relationship between physical 
exercise and psychosocial and occupational stress, age, drugs, gender, smoking, alcohol, and 
sleep [179-182]. Although there are advantages in using HRV methods, however, these 
methods are influenced by multi-factors such as stress, cardiac diseases and pathological states 
[183, 184]. Unlike Ewing battery tests, performing HRV tests does not demand laborers with 
professional skills. On top of this, there are several HRV tracking Apps employed in 
smartphones aggregated with a finger-wave pulse sensor or heart rate strap for easy daily 
monitoring [185, 186]. The remarkable advance in analysis methods such as the new 24-h 
multi-channel electrocardiographic recorders, digital, high frequency, statistical indices in the 
time and frequency domains, has significantly contributed to making HRV assessment more 
comfortable [119]. The required time to perform HRV test is short, about 1 minute while Ewing’ 
tests require from 20 to 30 minutes. It is possible to perform HRV tests in many positions, for 
example, e either a supine, standing or seated position. The disturbance in heart rhythm and the 
analysis of the interbeat intervals provide additional diagnostic information that can be 
incorporated into a clinical model of CAN’s diseases.  
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5.4  The Framework of the Predictive Model  
This section explains the framework that was applied in constructing the predictive model of 
CAN using HRV methods as presented in Figure 5-3.  
 
Figure 5-3. Graphical description of building the predictive model. 
5.4.1 Dataset  
A real dataset was used to evaluate the performance of the predictive model. The dataset was 
used from the diabetes complications screening research initiative known as DiScRi project 
[35]. In the present model, we have included only EBT, HRV tests and QRS test which has 
shown as indicative for CAN’s disease [187] as presented in Table 5-1. Since there are few 
participants with severe and atypical categories of CAN’s disease, all their instances and those 
involving the participants with normal, early, and definite categories have been deleted. 
Missing values of tests are widespread in medical data [188, 189]. Thus the preparation of the 
data for this study was done by imputing the missing values. These missing values were 
replaced by the mean and mode value of the feature. Hence, a complete dataset without any 
missing value was achieved. 
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Table 5-1. The included features  
Feature Description 
LSHR “Lying to Standing Heart Rate change.” 
DBHR “Deep Breathing Heart Rate change.” 
VAHR “Valsalva manoeuvre Heart Rate change” 
HGBP “Hand Grip Blood Pressure change.” 
LSBP “Lying to Standing Blood Pressure change.” 
SDNN “The standard deviation of the NN intervals 
RMSSD The square root of the mean squared difference of the NN intervals.” 
Total Power “Variance of NN intervals over the temporal segment (freq < 0.4)” 
LFms “Power in the low-frequency range (freq 0.04 to 0.15)” 
HFms “Power in the high-frequency range (freq 0.15 to 0.4)” 
LFnu “Power in normalized units LF/(Total Power–VLF)*100.” 
HFnu “Power in normalized units HF/(Total Power–VLF)*100.” 
LFln “Natural logarithm of LF” 
HFln “Natural Logarithm of HF” 
ApEn “Approximate entropy.” 
SampEn “Sample entropy “ 
DFAα1 “Detrended fluctuation analysis for short-term fluctuation slope.” 
DFAα2 “Detrended fluctuation analysis for long-term fluctuation slope.” 
ShanEn “Shannon entropy.” 
QRS axis “The total of electrical energy generated from 3 waves.” 
 
5.4.2  Features Selection  
Feature selection is a significant field in data mining which saves effort [190]. The primary aim 
of feature selection methods is to select the best features which can be used in constructing the 
prediction model and furthermore improve the accuracy of the model [191]. Using features 
selection methods mainly contributes to reducing the irrelevant or redundant features, dataset 
dimensionality, runtime, costs, as well as facilitating data visualization [191, 192]. Medical 
dataset often contains a large number of features (tests) which influences the process of 
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decision making [193]. Exploiting features selection methods with medical dataset results in 
abundant consequences such as reducing the effort of doctors to make a decision, increasing 
the accuracy of decision-making, as well as decreasing the economic burdens of unnecessary 
tests. 
In general, Features selection methods, are classified into filtered, embedded and 
wrapper [194]. Filter methods are defined as pre-process steps that use the statistical 
measurement to specify a score for each tested feature. Although filter methods are easy in 
computation, scalable, fast, and independent, these methods, however, do not take into 
consideration the association between features and the employed classifiers [195]. As for 
wrapper methods, features are selected according to the employed classifier (dependent) [196]. 
These methods have many advantages such as simplicity, taking into account the dependencies 
between features and reacting with the used classifier. Using such methods, however, may 
result in an overfitting problem as well as the requirement for more computation. Embedded 
methods are quite similar to the wrapper methods, but they are intrinsic model building metrics 
that are used during learning [197]. These methods interact with the used classifier; consider 
the dependencies between features, unlike wrapper methods such methods do not demand 
complex computations.  
Choice of feature selection methods, in general, depends on multi-considerations like 
the accuracy of classification, stability, simplicity, number of reduced features, storage and 
computational requirements [198]. According to the advantages and disadvantages mentioned 
above of the features selection methods, this study used the embedded methods in the present 
model. More specifically, the current study used mean decrease accuracy (MDA) features 
section implemented in the random forest (RF) [32, 33]. It is capable of addressing the most 
common problems such as prediction problems, regression, and features selection [199]. RF 
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does not demand complex computations and covers the impacts of feature dependencies [193]. 
As such, this current study used (MDA) features selection implemented RF.  
In general, MDA uses permuting Out-Of-Bag (OOB) samples to calculate the 
significance of features [193]. The OOB sample is a group of observations that are not use in 
constructing of the current tree. OOB sample is used to measure the prediction error of features 
and based on that conducts the importance of each feature [200]. There are three steps to 
measure the OOB importance error: 
1. Record prediction error for each tree (Error rate (ER) for classification, mean square 
error (MSE) for regression). 
2. Repeat the first step after permuting each predictor feature.  
3. Calculate the average of the differences between step 1 and 2 based on the following 
equation 
Feature importance𝑗 =  
1
𝑛𝑡𝑟𝑒𝑒
 ∑ (𝐸𝑃𝑡𝑗 −  𝐸𝑡𝑗
𝑛𝑡𝑟𝑒𝑒
𝑡=1  ) (1). 
Where the ntree refers to the number of trees in the forest. Eij represents the OOB error of tree 
t before permuting (first step). Epic indicates to the OOB error of tree t after permuting (second 
step). Feature with high MDA value indicts to the most important feature; for more details 
kindly refer to [201].  
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5.4.3 The Investigated Algorithms.  
In this section, we have presented the base and ensemble classifiers that have investigated to 
build the predictive model.  
5.4.3.1 The Base Classifiers 
In this subsection we have briefly explained the investigated base classifiers to build the 
predictive model, all of them were available in Weka [31]. The classifiers have chosen due to 
their superior performance in solving various real-life problems. In the following a brief 
description for each one:  
5.4.3.1.1 Random Forest (RF)  
 
Random Forest (RF) has firstly introduced by [202] which is one of the most popular ensemble 
method based on decision trees. Such a method is capable of dealing with multi-tasks like 
classification, regression, and features selection. It has shown an ability to handle missing 
values and massive dataset with high dimensionality. It is a consensus' modeling method that 
results in more accurate predictions based on gathering several decision trees. The mechanism 
work of random forest algorithm consists of multi-steps: first, constructs several decision trees 
using randomly selected training subset based on Gini impurity, information gain or any 
decision tree algorithms. Afterward, it collects the votes of prediction from the decision trees 
to determine the final class of the tested object using the bootstrap aggregating method. It 
consequently eliminates the objects with low rank based on the heuristics of empirical 
performance. Using such method importantly contributes in reducing the variance. The general 
formula of Gini impurity is:  
𝐺𝑖𝑛𝑖 =  ∑ 𝑃𝑖 (1 −  𝑃𝑖  )
2
𝑖=1
 (2).   
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The training algorithm of random forest uses bootstrap aggregation technique with tree learners 
as follow. 
𝑓 =  
1
𝑁
 ∑ 𝑓𝑛(?́?)
𝑁
𝑛=1
  (3).  
Where 𝑁 represents the repeated number of selected random samples with replacement by 
bootstrap aggregation, and ?́? donates to unseen samples. After training, the prediction for ?́? can 
be made by vote or averaging.  
5.4.3.1.2 Projective Adaptive Resonance Theory (PART) 
 
Projective Adaptive Resonance Theory (PART) is a combination of the decision tree (C4.5) 
and repeated incremental pruning to produce error reduction (RPPER) classifiers [203]. It is a 
useful classifier for learning decision lists by using the repeated generation of partial decision 
trees in a separate-and-conquer way. Such a method works in two stages. First, it induces a rule 
set then purifies it using a sort of complicated optimization that dismisses (C4.5) or adjusts 
(RPPER).    
5.4.3.1.3 Sequential Minimal Optimization (SMO) 
 
Sequential Minimal Optimization (SMO) classifier has proposed to apply sequential minimal 
optimization in the training of the support vector classifier [204]. The primary aim of this 
method is to solve the quadratic programming problem (QP), which arises during the training 
of the support vector classifier [205]. To tackle this problem, SMO divides the problem of QP 
into a series of smallest possible QP subproblems and solve it analytically. The following 
equation explains the geranial equation for SMO: 
𝑚𝑎𝑥 ∑ ∝𝑖− 
1
2
𝑚
𝑖=1  ∑ ∑ 𝑎𝑖 𝑎𝑗  𝐾(𝑏𝑖
𝑚
𝑗=1
𝑚
𝑖=1 , 𝑏𝑗)  ∝𝑖 ∝𝑗  (4).  
 
Where 𝐾(𝑏𝑖, 𝑏𝑗) refers to the kernel function, and ∝𝑖 for Lagrange multipliers. 
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5.4.3.1.4 Instance-Based learning (IBK) 
 
The instance-based learning is also known as (memory-based learning) introduced by [206]. In 
Weka called instance-bases learning with parameter k (IBK).  This method compares new 
instances of a problem with instances that have trained, instead of performing explicit 
generalization [207]. This method directly creates hypotheses using the training dataset. The 
general work of this method depends on the Similarity function which describes as follow: 
𝑆𝑖𝑚𝑖𝑙𝑎𝑟𝑖𝑡𝑦 (𝑛, 𝑚) =  − √∑ 𝑓(𝑛𝑖 , 𝑚𝑖
𝑘
𝑖=1
)  (5). 
Where 𝑛 refers to the trained instances of 𝐾 feature and 𝑚 donates to tested instances of the 
same feature.  
5.4.3.1.5 Naïve-Bayes/Decision Tree (NBTree)  
 
A hybrid classifier uses a decision tree with naïve Bayes classifiers at the leaves [208], which 
uses the advantages of both methods. More specifically, the classifier trains Naïve Bayes 
classifier in the decision regions of C4.5 algorithms. The general formula of Naïve Bayes 
classifier which calculates the posterior probability is:  
𝑃(𝑐|𝑓) =
𝑃(𝑓 |𝑐) 𝑃(𝑐)
𝑃(𝑓)
  (6). 
Where 𝑃(𝑐|𝑓) donates to the posterior probability and 𝑃(𝑓 |𝑐) is the likelihood of f belong to 
c. 𝑃(𝑓) and 𝑃(𝑐) are the prior probability for feature and class respectively. C4.5 algorithms 
use information gain or entropy to build the trees that are presented in equations (7) and (8). 
5.4.3.1.6 J48  
 
J48 is a decision tree classifier which proposed to enhance the performance of the classification 
and regression trees (CART) algorithm [209]. J48 is set of generated pruned or unpruned 
decision trees. Such classifier uses information gain function to construct a tree, whereas best 
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feature with highest information gain is selected as a node (split point). Each leaf node in the 
constructed tree refers to a decision or classification. The formula of information gain function 
of feature 𝑋 at the node is: 
𝐼. 𝐺(𝑌, 𝑋) = 𝐸𝑛𝑡𝑟𝑜𝑝𝑦(𝑋) −  ∑ (
| 𝑌𝑥|
| 𝑌|
)
𝑥∈𝑋
 𝐸𝑛𝑡𝑟𝑜𝑝𝑦(𝑌)  (7). 
Where Y refers to the instances set on that node;   |𝑌| is the number of instances in 𝑌 ; and  𝑌𝑥 
donates the sub-set of 𝑌 for feature 𝑋 with value 𝑥.  
The following equation is used to calculate the Entropy of set 𝑌: 
𝐸𝑛𝑡𝑟𝑜𝑝𝑦(𝑌) =  ∑ − 𝑝𝑖  log2 𝑝𝑖 
𝑛𝑜.𝑜𝑓 𝑐𝑙𝑎𝑠𝑠𝑠𝑒𝑠
𝑛=1
 (8). 
Where 𝑝𝑖 refers to the instances ratio in set 𝑌 with 𝑛
𝑡ℎ  class as output feature.   
5.4.3.2 The Meta-Classifiers 
 
In statistics and machine learning, ensemble methods are processes that use multi-learning 
classifiers to obtain a robust predictive performance than could be obtained from a single 
classifier [210, 211]. The primary aim of such ensemble methods is to cover the weakness of 
single classifiers [212]. In comparison to the single classifiers, there are many robust evidences 
confirmed that the use of ensemble classifiers could be more effective [213]. Nevertheless, this 
is not applicable for all base classifiers. In general, ensemble methods build on combined 
predictions results made by several base classifiers. These methods form a promising research 
direction in machine learning due to several characteristics such as computational, statistical 
and representational [214]. In this subsection, we have provided an overview of ensemble 
methods that examined in our model, which performed well for our dataset.  
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5.4.3.2.1 AdaBoost  
AdaBoost is a sequential learning process that used in classification problems, aims to cover 
the weakness resulting from the learning algorithm [215]. AdaBoost method repeatedly runs a 
weak classifier with multi distributed training samples. Such an ensemble method allocates 
weight for each instance in the training dataset. The ensemble initially allocates equal weights 
for all instances, and then it increases the weight value of misclassified instances in the weak 
classifier and reduces the weight value of the correctly classified instances in each iteration. At 
the end, the weighted voting is used to obtain the final derive results [212]. For more details 
kindly refers to [215]. The following formula represents a boosted classifier. 
𝐹𝐿(𝑥) =  ∑ 𝑓𝑙(𝑥)
𝐿
𝑙=1
  (9) 
Where 𝑓𝑙 refers to a boosted classifier with 𝑥 objects as input to return the class value of 
𝑥 objects.  
5.4.3.2.2 Bagging  
Bagging ensemble method has introduced by [216], which aims to enhance the accuracy and 
the stability of classification and regression algorithms. Bagging ensemble method handles 
samples simultaneously. The working mechanism of an ensemble concentrates on dividing the 
training dataset into multiple random samples with a replacement called bootstrap samples. 
The created sets called bootstrap samples. The prediction results of each classifier are then 
combined based on average or a majority of voting. The ensemble is capable of decreasing 
variance and avoids the problem of over-fitting, and works with a limited amount of data. Such 
an ensemble is often preferred to use with low bias and high variance models [217]. Although 
bagging ensemble was designed to work with decision tree methods, it has shown proficiency 
to work with various classifiers. Such ensemble considers a particular case of averaging 
approach. The general formula of bagging represents as follow : 
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𝑓(𝑥) =  
1
𝐶
 ∑ 𝑓𝑐(𝑥)
𝐶
𝑐=1
 (10)  
Where 𝐶 is the number of different created trees trained on randomly selected sub-sets with 
replacement. 
5.4.3.2.3 Dagging  
Dagging ensemble classifier is similar to bagging ensemble classifier, except that it uses 
disjoint stratified samples instead of bootstrap samples. The ensemble divides the training data 
into disjoint stratified samples and trains samples at same base classifiers [218]. The result of 
each trained classifier is then collected using majority voting method. Such ensemble, in 
general, is suitable to work with slow base classifiers. 
5.4.3.2.4 Decorate  
(DECORATE) Stands for diverse ensemble creation by oppositional re-labeling of artificial 
training examples. Such ensemble iteratively generates several ensembles of classifiers via 
creating artificial training examples [219]. The following equation is employed to compute the 
probabilities of class membership in the entire ensemble.  
𝑃𝑛(𝑚) =  
∑ 𝑃𝐶𝑏,𝑛(𝑚)𝐶𝑏 ∈ 𝐶∗
|𝐶∗|
  (11) 
Where 𝐶𝑏 is a base classifier, 𝐶
∗ supplies the probabilities of the class membership 𝑚. 𝑃𝑛(𝑚) 
donates to the probability of 𝑚 belongs to class 𝑛. The ensemble then chose most the probable 
class with the highest probability.  
5.4.3.2.5 MultiBoost  
MultiBoost is an extension of AdaBoost ensemble classifier that is used wagging technique 
[220]. Such method builds multi sub-committees contain multi trees instead of a set of single 
classifiers as used in the AdaBoost ensemble. Wagging is an alternative to bagging, where the 
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weights of trained instances that generated during boosting are used to select bootstrap samples 
[221]. 
5.4.3.2.6 Stacking  
Stacking ensemble considers an extension of the voting ensemble. Such an ensemble is capable 
of handling classification and regression problems. The working mechanism of this ensemble 
consists of two stages: firstly, it uses multiple base classifiers to predict the outcome. A new 
meta-classifier is then used to combine the outcomes of the evaluated classifiers in the first 
stage as additional inputs. Using stacking ensemble significantly contributes to decreasing 
either bias or variance error depending on the used classifiers.  
5.4.4 The Predictive Model of CAN 
In this subsection, we explore the predictive model of CAN based on Ewing’s tests combined 
with HRV methods. Figure 5-4 illustrates the working mechanism of the predictive model.  
 
Figure 5-4. The Predictive Model 
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As evident from Figure 5-4, the model comprises from two level. The first level of the model 
contains the very best classifier in the case study of this chapter. Afterward, outputs of all base 
classifiers (very best classifier) then pass to the upper level (best Meta classifier). In turn, the 
Meta classifier combines all outputs of base classifiers and applies its’ own algorithm, to make 
the final decision for the entire constructed model. The directions of arrows in the diagram 
represent to the direction of data follow in the model. 
Although the whole model might contain a large number of generated base classifiers, the Meta 
classifier will automatically handle this issue. The predictive model can automate the process 
of generating a large number of classifiers under one schema. It is easy and straightforward to 
employ using both Weka SimpleCLI command line and the graphical user interface (GUI). It 
is normal to anticipate that the predictive model will improve the performance better than the 
base classifiers that incorporated in its construction. This attributed to the aggregation of 
strengths of these methods. The resample strategy that used in this model also helps to improve 
the performance and overcome the overfitting issue. The predictive model can clearly show 
that such models can surprisingly exceed the traditional algorithms in performance. It is also a 
helpful tool in the field of medical analysis that can further improve several other domains.  
5.4.5 Experimental Setup 
Many bases and ensemble classifiers have assessed to build the predictive model as listed in 
subsection 5.4.3. All the investigated base and ensemble classifiers are available and applied 
using Weka version 3.9 [31]. Weka is a popular tool for the collection of machine learning 
algorithms that widely used in data mining [31]. All experiments have implemented on HP PC 
with Intel corei7 CPU processor.  
At first, we run preliminary tests for all the base classifiers, then choose higher performance 
one to be a base classifier for the Meta classifiers. Afterward, we examined the performance of 
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our investigated ensemble classifiers using the best-selected base classifier. The ensemble 
classifier with the highest performance has chosen to be ensemble classifiers of the predictive 
model. All base and ensemble classifiers applied using their default settings.  
5.4.6 Evaluation Metrics  
Accuracy (number of participants that are correctly classified) has used as the primary 
measurement to evaluate the performance of the predictive model. The accuracy of 
classification has presented in equation (12), which exposes the total number of participants 
that correctly classified with the positive and negative disease.  
𝐴𝑐𝑐𝑢𝑟𝑎𝑐𝑦 =  
𝑇𝑃+𝑇𝑁
𝑁
 (12)   
Where 𝑇𝑟𝑢𝑒 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒 (𝑇𝑃) refers to the number of participants that are correctly predicted 
with a positive result, whilst 𝑇𝑟𝑢𝑒 𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒 (𝑇𝑁) denotes to the number of participants that 
are correctly predicted with negative result. We also calculated the Area Under Curve (AUC) 
which also known as Receiver Operating Characteristic (ROC) in order to compare with the 
existing work 
In all experiments, we have applied 10-fold cross-validation (CV) approach to obtain a 
balanced evaluation of the generalisation error. Using 10-fold CV divided the included dataset 
randomly into 10 subsets: 9 subsets have employed for training stage (90%), and the remaining 
subset has exploited for the testing stage (10%). Such procedure then repeated 10 times with 
replacement in the folds. The average of testing results then calculates to obtain a final one.  
 
 
 
 90 
 
5.5  Results and Discussions 
In this section, we presented the performance and the obtained results as follows.  
5.5.1 The Performance of Features Selection Method 
In this experiment, we have used random forest based on the mean decrease accuracy (MDA) 
using R language. This method ranks features based on to their importance to the target feature, 
as presented in Figure 5-5.  
 
Figure 5-5. The Importance of Features by (MDA). 
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In this regards, to get the most important features (an optimal subset of features), we have tested 
the performance of random forest base classifier. We have sequentially included the ranked 
features in the test based on their importance (starting with the highest rank feature) and adding 
more features as long they are improving the accuracy. We have repeated the previous step 
until the accuracy started in decreasing. 
The result of the experiment has concluded six essential features of HRV methods in addition 
to EBT, we named it as an optimal subset of features. The most important features of the 
optimal subset were LSHR, DBHR, VAHR, ShanEn, HGBP, LSBP, Total power, SampleEn, 
LFln, LFms and HFln. To confirm the feasibility of the selected features (optimal subset), we 
have tested them with the rest base classifiers. The results of tests have also confirmed the 
feasibility of the selected features. All results of the tested base classifiers for all features and 
optimal subset presented in Figure 5-6.  
The results have confirmed the feasibility of these features. The results of experiments have 
also demonstrated that random forest base classifier steadily outperformed all other tested base 
classifiers as presented in Figure 5-6. The high performance of random forest base classifier 
attributed to its ability to construct many decision trees during the training step [222]. The 
popularity of random forest further comes from its excellent performance compared to other 
algorithms [223]. It has therefore used as a base classifier for our proposed model. 
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Figure 5-6. The accuracy of base classifiers  
The effectiveness of the selected HRV features is attributed to several reasons. For instance, 
LFln, LFms, HFln and Total power features have widely used in multi diseases diagnosing. 
Spectral heart rate variability methods offer additional tests can be exploited for prediction 
CAN [52]. These methods are used as the non-invasive parameters to assess the autonomic 
nervous system modulation [224]. They are also an excellent tool to measure the oscillations 
over any given period [225, 226]. As for the entropy measures have also shown their ability in 
HRV analysis [227]. Sample entropy (SampEn) uses for assessing the complexity of 
physiological time-series signals, diagnosing diseased states [228, 229]. 
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5.5.2 The Performance of HRV Features with Incomplete Ewing Tests. 
In this experiment, we have evaluated the contribution of the selected HRV’s features 
combined with an incomplete set of Ewing’s tests. To achieve that we have removed one of 
Ewing’ tests in each time and evaluate their contribution. Figure 5-7 demonstrates the result of 
experiments. 
 
 
Figure 5-7. Accuracy of RF for HRV Features with Incomplete Ewing’ Tests. 
As presented in Figure 5-7, the selected HRV features have proven the accuracy of prediction 
with an incomplete set of Ewing’s test. Thus, HRV features could be used as alternative 
predictors to enhance the prediction accuracy when one of the Ewing battery tests is missing  
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5.5.3 The Performance of the Predictive Model and Validation 
In this experiment, we have examined the performance of the selected ensemble classifiers in 
our investigation. As mentioned previously, due to the superiority of random forest in 
comparison to the other base classifiers, it has used as a base classifier with all the tested 
ensembles. The results of the tested ensembles presented in Figure 5-8. The results have shown 
that some of the tested ensembles improved the predictive accuracy of the model. The very 
best obtained results in the predictive model were by AdaBoost and MultiBoost with a 
predictive accuracy of 95% and ROC (0.978).  
 
Figure 5-8. Accuracy of Ensemble classifiers with the Optimal Subset  
Figure 5-9 presented the comparison between the predictive model and the most recent work 
in [73]. The comparison indicated that our model was higher ROC compared to the existing 
work. The predictive model has explicitly shown the most important features of HRV that can 
importantly contribute to improving the prediction of CAN’s disease with a complete and 
incomplete set of Ewing’ tests.  
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Figure 5-9. Comparison of our proposed models with MLASC. 
5.6  Chapter Summary 
In this chapter, we have built a predictive model to improve the predicting of CAN using Ewing 
battery tests combined with HRV methods. Many base and ensemble classifiers have 
investigated to build the predictive model. Random Forest base classifier outperforms all other 
examined classifiers. Therefore, it has chosen as a base classifier for our model. Adaboost and 
Multboost ensemble classifiers have achieved a very best performance for the predictive model 
with a predictive accuracy 95% and ROC (0.978). Random forest feature selection using MDA 
has used in deducing an essential HRV features. The most significant HRV features were 
ShanEn, Total power, SampleEn, LFln, LFms and HFln. These features achieved further 
improvement for CAN’s disease prediction, as well as they could be used as alternative tests 
in case one of Ewing’s tests is missing.  
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Chapter 6: Prediction of Cardiac Autonomic Neuropathy 
Disease using Logistic Regression 
This chapter addresses a significant challenge, which is how to predict the probability of CAN 
disease occurrence. The current study developed a predictive model to predict the probability 
of CAN disease occurrence using Ewing’s tests. This model significantly helps patients and 
doctors to be aware of the progress of the disease so as to recommend timely amd appropriate 
intervention. 
6.1 Introduction 
Cardiac Autonomic Neuropathy (CAN) represents one of the most severe forms of diabetes 
disease complications [21]. The occurrence of this disease is attributed to the increase in blood 
sugar levels (hyperglycemia) if other risk factors are excluded. The presence of disease 
significantly weakens the cardiac nerve fibers that innervate the heart muscle and blood vessels, 
subsequently resulting in irregular heart rate [12, 13]. According to the meta-analysis study of  
[230], among 15 studies the cardiovascular autonomic neuropathy (CAN) disease was a risk 
factor for mortality with (odds:  2.14, P < 0.000). Timely diagnosis of CAN’s disease is therefore 
essential to prevent the prevalence of a disease or reduce the potential risks consequences [158]. 
Although there has been extensive research done to provide a definitive therapeutic 
approach for CAN, however, no particular approach has been developed to date  [231]. This gap 
indicates that the disease needs further investigation. Many studies have been carried out to 
diagnose CAN disease using Ewing battery tests combined with various risk factors [7, 67-72]. 
Although there have been some excellent performances from the many models that are the 
products of these studies, the disease's progress remains obscure for patients and specialists to 
provide timely intervention and increase patient awareness. 
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Using machine-learning capabilities in the healthcare field has shown significant 
contributions in term of diagnosing. For example, Stanford University has used a deep learning 
algorithm to diagnose skin cancer [232]. Google has developed a machine-learning algorithm 
helps in identifying the cancerous tumors on mammograms[233]. Hence, developing an 
accurate automated machine-learning model significantly participates in reducing the number 
of patients with CAN subsequently reduction the mortality that related to CAN. In this chapter, 
we develop a predictive model exploiting logistic regression capabilities. The model predicts 
the likelihood of CAN occurrence based on Ewing’s Tests.  
The layout of the present chapter is as follows: Section 6.2 describes the problem while 
Section 6.3 provides the details of the methodology used in the presentation of this chapter. 
Results and discussion are provided in section 6.4. Finally, the Chapter Summary is in Section 
6.5. 
6.2  Problem Overview  
The traditional process of diagnosing cardiac autonomic neuropathy (CAN) depends Ewing 
tests. Many predictive models have been proposed to predict CAN disease-using Ewing tests 
combine with various tests.   
For example, Abawajy, et al. [7] proposed a multi-tier ensemble model called Automated 
Iterative Multi-tier Ensemble (AIME) to enhance the accuracy of CAN by using blood 
biochemistry features of the Ewing tests. Jelinek, et al. [67] investigated the neurological 
diagnostics of a CAN based on the five Ewing test attributes using a number of base and meta-
ensemble classifiers. An early method to enhance the classification of CAN’s disease was 
investigated in [68]. The proposed method used Ewing’s tests incorporated with additional 
attributes along with clinical data. Kelarev, et al. [70] also proposed ensemble classifiers using 
Ripple down Rules as a base classifier in the prediction of cardiovascular autonomic 
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neuropathy (CAN). Different work by Kelarev, et al. [71] has monitored patients with diabetes 
in pervasive healthcare. To address this issue, the authors used ensemble classifiers based on 
decision trees classifiers. They investigated various ensembles of classifiers using decision 
trees classifiers as a base classifier to choose the best accuracy ensemble. Another proposed 
model by Abawajy, et al. [72] suggested a Multi-tier Ensemble classifier to diagnose 
cardiovascular autonomic neuropathy (CAN) using QRS feature combined with a sub-set of 
Ewing’s tests.  
Despite the outstanding performance of these predictive models [7, 67-72]; however, they 
were only able to predict the categories of disease. For example, they would predict whether 
the patients have normal, early, definitive, severe or atypical CAN disease. The probability of 
CAN disease occurrence remains obscure.  
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6.3  Methodology 
This section explains the steps of constructing the prediction model, which is illustrated in 
Figure 6-1. 
 
Figure 6-1. A Graphical Description of the Proposed Model 
6.3.1 Dataset 
A real dataset was used to train and test the predictive model in the present chapter. The dataset 
was extracted from the diabetes complications screening research initiative (DiScRi) in 
Australia [35]. Although the DiScRi contains more than 200 tests related to CAN disease, in 
the present chapter, only the traditional tests of CAN as listed in Table 6-1 are used. These are 
the standard tests and notation of the disease by Ewing [11]. The disease is classified into five 
categories: normal, early, definite, severe, and atypical. These categories and the roles of 
classifying CAN’s disease are introduced in Table 6-2 [11]. In this current study, only 
participants with normal and early categories were included. According to the availability of 
normal and early categories, tests of 237 participants were carried out, and 132 participants 
were found to be healthy, while 105 were with an early stage of the disease.  
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Table 6-1.  Ewing Battery Tests. 
Notation Description 
LSHR “Lying to Standing Heart Rate change.” 
DBHR “Deep Breathing Heart Rate change.” 
VAHR “Valsalva manoeuvre Heart Rate change” 
HGBP “Hand Grip Blood Pressure change.” 
LSBP “Lying to Standing Blood Pressure change.” 
 
Table 6 -2. Standard Measurements of EBT 
Notation Normal Borderline Abnormal 
LSHR ≥ 1.04 1.01-1.03 ≤1.00 
DBHR  ≥ 15 11-14 ≤10 
VAHR ≥1.21 1.11-1.20 ≤1.10 
HGBP ≥ 16 11-15 ≤10 
LSBP ≤ 10 11-29 ≥ 30 
 
6.3.2 Logistic Regression  
One of most popular machine learning algorithms that used in classification and regression 
problems is Logistic Regression. This method has been commonly used to solve various 
problems in different fields of life such as health, financial, marketing... etc. The popularity of 
logistic regression comes from several reasons. For example, this method demands one or more 
independent variables to determine the outcome. Logistic regression is aimed to find the best 
model to describe the association between the included independent variables and the outcome 
(dependent variable).  
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Logistic regression estimates the likelihood of an outcome based on one or more predictors (or 
independent) variables (features) using a method called a logistic function (also called sigmoid 
function). The formula of the logistic model computes the probability of the outcome 
occurrence depending on the given independent variables. The general formula of logistic 
regression in terms of sigmoid function can be expressed as follows [234]: 
𝑃 =  
1
1 + exp− 𝑧
  (1)  
Where P is the likelihood of an outcome occurrence; and  z refers to the linear combination 
function including independent variables. 
  z can also be expressed as follows: 
z =  𝛽0 + 𝛽1𝑣1 + 𝛽2𝑣2 + ⋯ 𝛽𝑛𝑣𝑛  (2)  
where  𝛽0 is the expected mean value of P when all v = 0;  𝑛 refers to the number of the 
independent variables;   𝛽𝑛 is the regression coefficients of each independent variable which is 
the influence of each independent variable on the likelihood value (P). 𝑣𝑛 denotes the included 
independent variables.  
 
 
 
 
 
 102 
 
6.3.3 The Predictive Model  
In this section, the predictive model to predict the probability of CAN disease occurrence 
exploiting logistic regression capabilities is introduced. This model is simple and easy to use 
with various platforms and tools such as the R language. The predictive model provides both 
patients and specialists with a bright idea of the degree of disease progression, instead of a 
general description of the disease. Such useful knowledge facilitates the planning of timely 
intervention and also creates greater awareness of the risk of the disease.  
  To build the predictive model, the capabilities of logistic regression were exploited. By 
applying the linear combination function in equation (1) for the Ewing’s tests as independent 
variables to determine an outcome (CAN’s disease progress); the formula of the predictive 
model computes the probability of occurrence of CAN’s disease progress depending on the 
predictability of Ewing’s tests as expressed below:  
𝑃 =  
1
1 + exp(−(𝛽0+ 𝛽1𝐿𝑆𝐻𝑅+𝛽2𝐷𝐵𝐻𝑅+ 𝛽3𝑉𝐴𝐻𝑅+𝛽4𝐻𝐺𝐵𝑃+𝛽5𝐿𝑆𝐵𝑃)) 
  (3)  
Where: 
 𝑃 represents the probability of occurrence of an outcome (CAN’s disease progress) based on 
the selected independent variables.  
 𝛽 indicates the regression coefficients of each included Ewing’s test.  
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Table 6-3. The analysis of logistic regression 
Test Coefficient P value Odds Ratio Confidence interval (%) 
Intercept  28.88 0.000 3.48  
LSHR - 4.68 0.013 0.009  (0.000- 0.373) 
DBHR - 0.488 0.000 0.614  (0.53-0.711) 
VAHR -11.57 0.000 0.009  (0.00-0.001) 
HGBP - 0.197 0.000 0.821  (0.754-0.894) 
LSBP 0.11 0.003 1.116  (1.038-1.199) 
 
Later, logistic regression was used to calculate the coefficients of Ewing’s tests. Table 
6-3 presents the outcome of applying logistic regression using Ewing’s tests as independent 
variables and CAN disease as the dependent variable. As evident from Table 6-3, all Ewing’s 
tests have a significant association with the disease (P < 0.05) and therefore, have been included 
in the predictive model.  
As presented in Table 6-3, the coefficients of LSHR and DBHR tests were (𝛽LSHR = -
4.68; P =0.013) and (𝛽DBHR= - 0.488; P =0.000) respectively. The coefficients of VAHR and 
HGBP tests were (𝛽VAHR = -11.57; P =0.000) and (𝛽HGBP = -0.197; P = 0.000) respectively. As 
for LSBP the coefficient was ( 𝛽LSBP = 0.11; P =0.000). The outcomes of LSHR, DBHR, 
VAHR and HGBP tests showed negative 𝛽 coefficient values, which indicated their negative 
influence on the disease occurrence. On the other hand, the LSBP showed a positive 𝛽 
coefficient value, indicating it had a positive effect on the disease occurrence. Based on 
equation (3) and the outcomes in Table 6-3, the predictive model was built as follows:  
𝑃 =  
1
1 + 𝑒𝑥𝑝(−(28.88−
(4.68∗𝐿𝑆𝐻𝑅)−(0.488∗𝐷𝐵𝐻𝑅)−(11.57∗𝑉𝐴𝐻𝑅)−(0.197∗ 𝐻𝐺𝐵𝑃)+(0.11∗ 𝐿𝑆𝐵𝑃)))
 (4) 
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After constructing the predictive model of CAN disease, if new tests from the clinic are gained, 
for example, it is possible to use the predictive model to calculate the probability of CAN 
disease occurrence.  
The following cases are examples of applying the predictive model to determine the probability 
of CAN’s disease.  
Assuming the following Ewing’s tests for patient A are (LSHR = 1.35; DBHR = 9.4; VAHR = 
1.22; HGBP = 18; LSBP = 5); Patient B are  (LSHR = 1.066; DBHR = 4.74; VAHR = 1.2; 
HGBP = 36; LSBP = 9) and Patient C are (LSHR = 1.04; DBHR = 15; VAHR = 1.1; HGBP = 
16; LSBP = 9). By applying equation (4) with the tests of the three patients, the probability of 
developing CAN's disease of patient A can be calculated as follows: 
𝑃(𝐴) =  
1
1 +  exp(−( 28.88−(4.68∗1.35)−(0.488∗9.4)−(11.57∗1.22)−(0.197∗ 18)+(0.11∗ 5)))
= 0.703 
 
As for patient B, the probability of developing CAN's disease can be calculated as follows  
𝑃(𝐵) =  
1
1 +  exp(−( 28.88−(4.68∗1.066)−(0.488∗4.740)−(11.57∗1.2)−(0.197∗ 36)+(0.11∗9)) )
= 0.83 
 
Whereas the probability of patient C developing CAN's disease can be calculated as follows  
𝑃(𝐶) =  
1
1 +  𝑒𝑥𝑝(−( 28.88−(4.68∗1.04)−(0.488∗15)−(11.57∗1.1)−(0.197∗ 16)+(0.11∗9)) )
 = 0.86 
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6.3.4 The Evaluation of the Predictive Model 
A 10-fold cross-validation (CV) method was used to obtain a balanced evaluation of the 
generalization error. The 10-fold cross-validation (CV) method was used to randomly divide 
the entire dataset into 10 sub-sets: 9 sub-sets were employed for training stage (90%), and the 
remaining sub-set was exploited in testing stage (10%). This procedure is then repeated 10 
times with replacement in the tested folds. The standard measurements such as accuracy, 
sensitivity, speciﬁcity, Type I Error and Type II Error were calculated to evaluate the 
performance of the predictive model. The area under the curve (AUC) which is also known as 
receiver operating characteristic curve (ROC) is used to assess the performance of the model 
proposed for the current study. The ROC curve is an essential tool that is used for diagnose test 
evaluation. What follows below is description of the evaluation measures applied in the current 
study: 
 Sensitivity: represents the number of participants correctly predicted with a positive 
disease. 
𝑆𝑒𝑛𝑠𝑡𝑖𝑣𝑖𝑡𝑦 =  𝑇𝑃 (𝐹𝑁 + 𝑇𝑃)  (5)⁄  
 Speciﬁcity: depicts the number of participants correctly diagnosed with negative 
disease. 
𝑆𝑝𝑒𝑐𝑖𝑓𝑖𝑐𝑖𝑡𝑦 = 𝑇𝑁/(𝐹𝑃 + 𝑇𝑁)  (6) 
 Accuracy: exposes the total number of participants correctly predicted with the 
positive and negative disease.  
𝐴𝑐𝑐𝑢𝑟𝑐𝑦 = (𝑇𝑃 +  𝑇𝑁) (𝑇𝑜𝑡𝑎𝑙 𝑛𝑢𝑏𝑚𝑒𝑟) (7 )⁄     
 Type I Error: refers to the probability of diagnosing patients into normal group. As 
this is the opposite of sensitivity, a small value is a better value. 
𝑇𝑦𝑝𝑒 𝐼 𝐸𝑟𝑟𝑜𝑟 =  𝐹𝑁 (𝐹𝑁 + 𝑇𝑃)  = 1 −  𝑆𝑒𝑛𝑠𝑖𝑡𝑖𝑣𝑖𝑡𝑦  (8)⁄  
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 Type II Error: indicates the probability of diagnosing control people into early 
group, it is opposite of speciﬁcity, a small value is better 
𝑇𝑦𝑝𝑒 𝐼𝐼 𝐸𝑟𝑟𝑜𝑟 =  𝐹𝑃 (𝐹𝑃 + 𝑇𝑁)  = 1 −  Speciﬁcity  (9)⁄  
 
6.4  The Performance of the Predictive Model 
In this section, the experimental results obtained by the predictive model are presented. Table 
6-4 shows the confusion matrix of the predictive model. As is evident in the confusion matrix, 
the predictive model has achieved an outstanding performance with predictive accuracy of 
(87.31%). The model has correctly predicted 119 healthy participants out of 132 and 88 early 
patients out of 105. 
Table 6-4. The Confusion Matrix 
Class Normal Early 
Normal 119 13 
Early 17 88 
 
The sensitivity and the specificity achieved by the predictive model were also very good 
with 87.12%, and 87.5% respectively. As for Type I Error, and Type II Error of the predictive 
model, they were 12.88% and 12.5% respectively. This indicates that the proposed model can 
be efficiently used to predict the probability of CAN disease occurrence. It is also possible to 
exploit such a model with different health conditions.  
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Figure 6-2. ROC curve of the Predictive Model 
Table 6-5. The area under the curve of the Predictive Model. 
 
Area Under the Curve 
Test Result Variable(s): Predicted probability  
Area Std. Errora 
Asymptotic 
Sig.b 
Asymptotic 95% Confidence Interval 
Lower Bound Upper Bound 
0.962 0 .012 0.000 0.939 0.984 
 
Figure 6-2 presents the ROC curves of the predictive model and the details listed in 
Table 6-5. As shown in Table 6-5, the ROC of the predictive model is 0 .962% with 95% 
confidence interval (0.939- 0.984). Also, ROC is significantly different from 0.5 since P value 
is < 0.05 meaning that the proposed predictive model has predicted the group significantly 
better than by chance. 
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6.5  Chapter Summary 
Cardiac Autonomic Neuropathy (CAN) disease is one of the diabetes disease complications. 
The disease has been extensively investigated in many studies using various machine learning 
approaches and tests. All the existing works were however about predicting the categories of 
the disease. This chapter introduces a different predictive model that is able to predict the 
probability of CAN disease occurrence based on logistic regression advantages. The 
performance of the predictive model was outstanding and reliable. The accuracy of the 
predictive model was 87.31% and as for the sensitivity and specificity of the predictive model, 
they were 87.12% and 87.5% respectively. The study also calculated ROC to confirm the 
stability of the predictive model. The established ROC by the predictive model was 0.962%. 
The model is very efficient and straightforward to use by doctors as well as patients if they have 
the results of Ewing battery tests. The predictive model also confirmed that Ewing’s Tests were 
significant predictors of Normal and Early categories of Cardiac Autonomic Neuropathy (CAN) 
with (P < 0.05).  
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Chapter 7: Multi-diseases Prediction Modelling of 
Diabetes Mellitus and Cardiovascular disease by Common 
Risk Factors 
This chapter focuses on the description and explanation of a significant challenge, which is 
how to predict diabetes and cardiovascular diseases simultaneously. This study developed a 
predictive model for predicting diabetes and cardiovascular diseases simultaneously using their 
common risk factors. The predictive model exploits the predictive strength of common risk 
factors. Controlling these diseases significantly helps to reduce the prevalence of CAN.  
7.1 Introduction 
Diabetes mellitus (DM) is considered one of the most widespread noncontagious diseases 
worldwide [122, 235, 236]. This disease occurs due to the weakness of the pancreas in 
producing enough insulin or due to the body resistance to using the produced insulin. The 
number of people with diabetes continues to rapidly increasie. For example, the number of 
people with diabetes is expected to rise from 382 to 592 million by 2025 [237]. One in every 
10 people is likely to develop diabetes by year 2040 [238]. According to World Health 
Organization (WHO) estimation, DM was the leading cause of 1.6 million deaths in 2015 [239]. 
The economic burdens of diagnosing DM in the USA in 2017 was US$327 billion; of these 
US$237 billion was for direct medical costs and the rest in reduced productivity [240]. It is, 
therefore, crucial to concentrate on high-risk groups of people with diabetes in order to 
significantly  decrease the disease’s complications [79].  
Cardiovascular disease (CVD) is a set of diseases and disorders that affects the heart 
and blood vessels [241]. The WHO estimates that CVD is the leading life-threatening disease 
worldwide as presented in Figure 7-1 [242].  
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Figure 7-1. Overview of the global distribution of death due to chronic diseases  
CVD is in fact the leading cause of mortality. For example, in 2015 about 17.7 million 
people died because of CVD [243]. This disease was mainly responsible for the deaths of 
45,392 Australians in 2015, which translates into a worrying one death every 12 minutes [244]. 
About 10% of the global disease burden is related to CVD [241], and about 15% of the total 
financial burden in Australia [245]. This confirms the need for a viable approach that can help 
people to recognize and avoid the CVD risks sand subsequently reduce the high cost of medical 
expenses. 
Ample evidence has confirmed the association between DM and CVD. For example, 
most of the CVD risk factors such as hypertension, obesity, and dyslipidemia have been found 
in DM [19]. Type 2 DM is a primary risk factor for cardiovascular diseases [246, 247]. The 
presence of these diseases simultaneously significantly contributes to the increasing mortality 
rate [248, 249]. People with DM and CVD are 1.7 times more likely to die from CVD/DM 
compared to those suffering from CVD only [250]. CVD causes mortality and morbidity for 
Cardiovascular 
Diseases, 37%
Respiratory 
diseases, 8%
Cancer, 27%
Other NCDs, 23%
Diabetes melitus, 
4%
THE GLOBAL PREVALENCE OF CHRONIC DISEASES 
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DM patients; therefore the diabetes treatment should focus on the risk of CVD among DM 
patients [19].  
Both diseases, CVD and DM, are directly associated with cardiovascular autonomic 
neuropathy (CAN). For example, DM is the leading cause of CAN [157]. CAN is a primary 
risk factor for CVD and mortality in patients with diabetes [152, 251, 252]. It is therefore 
essential to provide a practical and viable model to predict these diseases to reduce the 
prevalence of CAN. Several studies have proposed different models to predict DM or CVD 
such as [75, 77-84]. These models, however, were developed to predict a single disease at a 
time, either DM or CVD, not both. Such proposed predictive models thus are unable to predict 
both diseases simultaneously. The abnormalities in physiological factors of CVD or DM often 
result in more than one disease at the same time [253]. Perceiving the risk of common factors 
and developing a predictive model for DM and CVD together is, therefore, more important 
than performing for only one disease. 
Utilizing  machine learning and data mining algorithms in diagnosing DM and CVD is essential 
to employing large available data of diabetes for extracting knowledge [254, 255]. This chapter 
introduces a two stages predictive model to predict DM and CVD simultaneously depend on 
their common risk factors. In particular, this study has investigated how risk factors of DM 
disease could be exploited to predict CVD disease and vice versa. The current chapter presents 
the following novel features:  
 Identifying the common risk factors of DM and CVD. 
 Building a predictive model capable of predicting DM and CVD simultaneously.  
The organisation of the chapter is as follows: Section 7.2 describes the problem and Section 
7.3 explains the framework of the Predictive Model. Results and discussion are presented in 
Section 7.4 followed by the chapter summary in Section 7.5. 
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7.2  Problem Overview  
Diabetes Mellitus (DM) and cardiovascular disease (CVD) are the most common chronic 
diseases that are closely associated with cardiovascular autonomic neuropathy (CAN). This 
indicates that controlling such diseases is crucial to reduce the prevalence of CAN. 
Many studies in the literature have proposed predictive models. For example, 
Alghamdi, et al. [75] proposed an ensemble machine learning method based on multiple 
classifiers to predict diabetes mellitus. The included base classifiers in the ensemble method 
were naïve bayes tree, random forest, and logistic model tree. Samant and Agarwal [77] also 
designed a model to detect diabetes disease using iris images. The authors examined several 
classifiers such as support vector machine, binary tree, adaptive boosting, neural network, 
random forest, generalized linear models, and selected the best one. Another model in [78] 
proposed intelligible support vector machines approach to diagnose diabetes mellitus using a 
real-life diabetes dataset. Wu, et al. [79] also provided a double-level algorithms prediction 
model to diagnose diabetes based on the improved K-means algorithm and the logistic 
regression algorithm. The provided model increased the accuracy by 3.04%. 
 As for CVD, Das, et al. [80] used neural network ensembles to identify heart disease 
using Cleveland Heart Disease Dataset (CHDD). Different work by Uyar and İlhan [81] led to 
the proposal of a genetic algorithm (GA) based trained recurrent fuzzy neural network (RFNN) 
to detect heart diseases. Another work in [82] created an early diagnosis of heart disease model 
based on heart sounds by using classification and regression trees. Masetic and Subasi [83] also 
built a predictive model of congestive heart failure by investigating many classifiers and 
selecting the best one. In this regard, the investigated classifiers were k-nearest neighbor, C4.5 
decision tree, artificial neural networks, support vector machine, and random forest. Yu and 
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Lee [84] also designed an approach to predict congestive heart failure (CHF) using UCMIFS 
selector and support vector machine (SVM). 
Despite the above models showed outstanding performances they were developed to 
predict single disease. Moreover, the models did not exploit the risk factors of one disease in 
predicting another disease and vice versa. 
7.3  The Framework of the Predictive Model  
In this section, the framework that is applied in constructing the predictive model as presented 
in Figure 7-2 is discussed.  
 
Figure 7-2. The Framework of the Predictive Model 
7.3.1 Dataset 
The dataset was collected from the diabetes complications screening research initiative 
(DiScRi) in Australia [35]. DiScRi is a large dataset, which contains more than 200 tests related 
to CAN. In this chapter, the most critical set of Ewing battery tests is involved, as well as blood 
biochemistry tests, in addition to the demographic data of the participants as presented in Table 
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7-1. Data of 812 participants were involved in this study, 244 participants were suffering from 
CVD, 237 with diabetes, 139 suffering from CVD and DM simultaneously, and 192 healthy 
disease-free participants.  
Table 7-1. The Covariates 
Covariates Description  
FH “Family history of the disease.” 
Gender “Male or Female” 
Age “Number of years.” 
BMI “Measure weight to height of participants.” 
W.C “Waist Circumference” 
HT Status “Hypertension status ( yes or no)” 
LSHR “Lying to Standing Heart Rate change.” 
DBHR “Deep Breathing Heart Rate change.” 
VAHR “Valsalvamanoeuvre Heart Rate change” 
HGBP “Hand Grip Blood Pressure change.” 
LSBP “Lying to Standing Blood Pressure change.” 
HbA1c “Hand Grip Blood Pressure change.” 
Triglyceride “Level of triglyceride in the blood.” 
Glucose 
The quantity of glucose in blood measured in (mmol/L); also called 
fasting glucose test (FGT) 
Screening glucose 
Level of glucose in the blood over time measured in (mmol/L); also 
called Glucose Tolerance Test (GTT) 
TC “Total cholesterol.” 
HDL “High-density lipoproteins.” 
LDL “Low- density lipoproteins.” 
TC/HDL ratio “Ratio of total cholesterol to high-density lipoprotein.” 
CVD status “Yes or No” 
DM status “Yes or No” 
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7.3.2 Extracting Common Risk Factors  
Although each disease could be attributed to several abnormal physiological factors, the 
abnormality of these factors often indicates some interrelated diseases. In this chapter, two 
feature selection methods are used in extracting the common risk factors of DM and CVD 
individually. The methods are a logistic regression (LR) [256], and the Evimp function (EVF) 
implemented in multivariate adaptive regression splines model (MARS) [257]. These methods 
were chosen due to their proficiency in determining the association between the independent 
variables and the outcome [258-260].  
7.3.2.1 Logistic Regression 
Logistic regression is considered one of the most common machine learning techniques usually 
used in medical research analysis. A power tool requires one or more independent variables to 
determine an outcome. This method clearly explains the relationship between the independent 
variables and the outcome variable. As presented previously in chapter 3 the general formula 
of logistic regression can be expressed in the following equation.  
log (
𝜋
1 −  𝜋
) =  𝛽0 +  𝛽1𝑥1 + 𝛽2𝑥2 + ⋯ 𝛽𝑛𝑥𝑛  (1). 
where 𝜋 represents the probability of occurrence of an outcome based on the selected 
independent variables (𝑥𝑛 ). 𝛽 Indicates the regression coefficients of each included 
independent variable. In the present chapter, logistic regression is used with a forward stepwise 
method to select the significant risk factors with (P <0.05).  
7.3.2.2 Estimate Variable Importance implemented in MARS  
The Evimp function (EVF) is a method implemented in multivariate adaptive regression splines 
model (MARS) [257]. EVF function returns a matrix presenting the relative significance of the 
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features in the model. The Evimp function (EVF) uses three criteria in estimating the 
importance of features as follows: 
 The (nsub-set) criterion calculates the number of sub-sets that involves the feature. 
Features that are involved in more sub-sets are considered most important. 
 The raw residual sum-of-squares (RSS) criterion contains two steps. Firstly, it computes 
the reduction in the RSS for each sub-set and compares the reduction with the value of 
the previous subset. After, for each involved feature, RSS aggregates these reductions for 
all sub-sets that involve the feature. In the end, the total aggregation of reductions is 
interpreted. Features that cause a massive reduction in RSS are most important.  
 The generalised cross-validation (GCV) criterion is similar to RSS criterion; however, it 
uses GCV instead of RSS. GCV evaluates the performance features in sub-sets and 
selects the most significant sub-set (lower values of GCV are useful). 
7.3.2.3 Voting Method 
After identifying the risk factors (statistically significant) of each disease by LR and EVF, a 
voting method is applied to determine the common risk factors between CVD and DM. The 
common risk factors refer to all factors that show a significant association in LR and EVF 
for both diseases. Correlation matrix method is then performed to remove the redundant 
common risk factors and avoid the problem of multicollinearity with (cutoff= 0.5). Dataset 
may include features that are strongly correlated with other features. Removing the redundant 
common risk factors significantly helps in reducing the load on the predictive model.  
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7.3.3 Building the Predictive Model based on the Common Risk Factors  
In the second stage, classification and regression (CART) algorithm [261] was used to 
construct the predictive model of DM and CVD using the extracted common risk factors in the 
first stage. CART was used due to its obvious long-list of advantages. For example, in 
comparison with other machine learning algorithms, CART outcomes visually are easy to 
interpret using If-then condition, which is like a human decision. It does not require specifying 
the association between independent variables and the outcome. As evident from its name, 
CART can handle both classification and regression problems. Further to these advantages, 
CART is capable of dealing with the continuous and discrete dependent variables. It 
automatically amends the constructed tree to reduce the impacts of the measured impurities, 
and identifies the efficiency of the node for a final decision.  
In general, CART algorithm uses Gini index to build the decision trees. Gini index measures 
the impurity or purity of the features. The general formula Gini index used by CART can be 
expressed as follows:  
𝐺𝑖𝑛𝑖 𝑖𝑛𝑑𝑒𝑥 =  1 − ∑  𝑝𝑖
2
j
𝑖=1
  (2). 
In fact, the initially constructed tree in equation (2) does not represent the optimal result. 
Therefore, CART algorithm prunes the created tree using node error rate as follows: 
𝑛𝑜𝑑𝑒𝑒𝑟𝑟𝑜𝑟 𝑟𝑎𝑡𝑒 =  𝑋𝑒𝑖 ∑ 𝑋𝑖
𝑖=1
⁄   (3). 
Where 𝑋𝑒𝑖 gives the number of misclassified instances in the node, and  ∑ 𝑋𝑖𝑖=1  provides the 
total number of instances in the node.  The process of pruning tree starts from bottom to top 
based on the total error rate condition. If the rate of total error is higher than the stated threshold, 
then it stops the process of pruning.  
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7.3.4 The Evaluation of the Predictive Model 
The 10-fold cross-validation (CV) approach was applied to obtain a balanced evaluation of the 
generalisation error. Cross-validation is an approach used to evaluate the performance of 
predictive models by partitioning the entire dataset into k number of sub-sets. It uses 10-fold 
cross-validation to randomly divide the entire dataset into ten sub-sets; 9 sub-sets are used for 
training stage (90%), and the remaining sub-set is used for the testing stage (10%) with 
replacement in the sub-sets. Various measures such as accuracy, sensitivity, speciﬁcity and 
confusion matrix measurements were calculated to assess the performance of the predictive 
model. All experiments were implemented using SPSS version 20.0 (SPSS, Inc., Chicago, IL, 
USA) and R language. Following is the describion of the evaluation measures used in the 
current chapter: 
 Sensitivity: defines the number of participants that are correctly predicted with the 
positive disease. 
𝑆𝑒𝑛𝑠𝑡𝑖𝑣𝑖𝑡𝑦 =  𝑇𝑃 (𝐹𝑁 + 𝑇𝑃)  (4).⁄  
 Speciﬁcity: refers to the number of participants that are correctly predicted with the 
negative disease. 
𝑆𝑝𝑒𝑐𝑖𝑓𝑖𝑐𝑖𝑡𝑦 = 𝑇𝑁/(𝐹𝑃 + 𝑇𝑁)  (5). 
 Accuracy: exposes the total number of participants that are correctly predicted with 
the positive and negative diseases.  
𝐴𝑐𝑐𝑢𝑟𝑐𝑦 = (𝑇𝑃 +  𝑇𝑁) (𝑇𝑜𝑡𝑎𝑙 𝑛𝑢𝑏𝑚𝑒𝑟) (6).⁄     
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7.4  Results and discussion 
This section presents the obtained common risk factors using LR and Evimp function (EVF). 
The rules and regulations of the predictive model in prediction multi diseases are then 
presented. 
7.4.1 Common Risk Factors of DM and CVD 
Table 7-2. shows the risk factors of DM selected by LR and the Evimp function (EVF).  
Table 7-2. Summarized risk factors of DM selected by LR and EVF. 
Covariates LR (EVF) Risk factors of DM 
FH  * * * 
gender * * * 
Age *   
W.C  *  
BMI    
LSHR * * * 
DBHR * * * 
VAHR  *  
HGBP    
LSBP * * * 
 HbA1c * * * 
Triglyceride    
Glucose * * * 
Screening glucose    
HT Status    
TC * * * 
HDL * * * 
TC\HDL ratio * * * 
LDL    
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As presented in Table 7-2, LR shows that FHDM, gender, age, LSHR, DBHR, LSBP, 
HbA1c, glucose, TC, HDL and TC\HDL ratio are significantly associated with DM (P < 0.05). 
The outcomes of applying an Evimp function (EVF) with DM demonstrates that FHDM, 
Gender, Waist circumference, LSHR, DBHR, VAHR, LSBP, HbA1c, Glucose, TC, HDL and 
TC\HDL ratio are most important features. Figure 7-3 illustrates the features’ importance of 
DM by Evimp function (EVF).  
 
Figure 7-3. Essential Features of DM by EVF 
Such tests showed significant association with DM due to many reasons. For example,  
HbA1c , and Glucose are very common and reliable tests for diagnosing diabetes ; both tests 
are recommended by the American Diabetes Association [118, 147]. As for FHDM, gender 
and age factors, DM is a complex disease influenced by multi-factors like genetics, lifestyle 
and environmental conditions [130]. TC, HDL and TC\HDL ratio also count significant 
predictors to predict type 2 diabetes [262, 263]. As for Ewing’s tests such as LSHR, DBHR, 
LSBP are the gold standard tests for CAN which is directly associated with DM.  
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In the same context, the risk factors of CVD selected by logistic regression (LR) and 
the Evimp function (EVF) are presented in Table 7-3. As is clearly shown obvious in Table 7-
3, applying LR reveals that FHCVD, gender, age, DBHR, LSBP, HbA1c, HT status, TC, HDL 
and TC\HDL ratio are importantly associated with CVD (P < 0.05). As for Evimp function 
(EVF), the result shows that FHCVD, Gender, Age, DBHR, LSBP, HbA1c, HT status, TC, 
HDL, LDL and TC\HDL ratio are significantly correlated with CVD. Figure 7-4 clarifies the 
feature significance of CVD by Evimp function (EVF). 
 
Figure 7-4. Essential Features of CVD by EVF. 
This significance of the concluded tests is attributed for several facts. For example, FHCVD, 
gender, age , and HT status are common risk factors for CVD  and used in the Framingham 
Risk Score (FRS) [264, 265]. Dyslipidemia is furthermore one of the main risk factors for CVD 
in DM [266, 267]. Increase in  HbA1c  showed progressively increasing risks of CVD [268]. 
As for the Ewing tests; it can serve as an independent prognostic indicator of sudden arrhythmic 
death risk [269].  
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Table 7-3. Summarized risk factors of CVD selected by LR and EVF. 
Covariates LR (EVF) Risk factors of CVD 
FH  * * * 
gender * * * 
Age * * * 
W.C    
BMI    
LSHR    
DBHR * * * 
VAHR    
HGBP    
LSBP * * * 
 HbA1c * * * 
Triglyceride    
Glucose    
Screening glucose    
HT Status * * * 
TC * * * 
HDL * * * 
TC\HDL ratio * * * 
LDL  *  
 
After the process of selecting the risk factors for each disease, the voting method was 
applied to manifest the common risk factors for both diseases as shown in Table 7-4. The 
common risk factors appeared to be a significant contribution by the two used techniques (LR 
and EVF) to both diseases. 
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Table 7-4. Common risk factors of DM and CVD. 
Covariates 
Risk Factors of 
DM 
Risk Factors of 
CVD 
The common risk 
factors 
FH  * * * 
gender * * * 
Age  *  
W.C    
BMI    
LSHR *   
DBHR * * * 
VAHR    
HGBP    
LSBP * * * 
 HbA1c * * * 
Triglyceride    
Glucose *   
Screening glucose    
HT Status  *  
TC * * * 
HDL * * * 
TC\HDL ratio * * * 
LDL    
 
As shown in Table 7-4, the common risk factors for both diseases are FH of the disease, 
gender, DBHR, LSBP, HbA1c, TC, HDL and TC\HDL ratio. These tests are essential for 
several reasons. For example, abnormalities in HbA1c tests lead to diabetes and heart diseases 
[118, 270, 271]. Compared to the level of low-density lipoprotein (LDL) cholesterol, the HDL 
cholesterol level is a robust risk factor for coronary heart disease and diabetes [272, 273]. The 
ratio of total cholesterol to HDL cholesterol is also a significant risk of cardiovascular events 
[267, 274, 275]. Presence of family history was found to be significantly correlated with the 
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prevalence of both diseases [57, 133].  
Later, the remove redundant features method was applied and showed there was 
inversely related correlation between TC feature and TC\HDL ratio with  𝑟 =  −0.8. 
Therefore, the TC feature was removed from the common risk factor set. Thus, the final set of 
common risk factors was FH of the disease, gender, DBHR, LSBP, HbA1c, HDL and TC\HDL 
ratio. 
7.4.2  The Performance of the Proposed Model 
Figure 7-5 depicts the obtained tree of the evaluation of participants with the final set of 
common risk factors of multi-diseases using the predictive model. As shown in Figure 7-5, 
HbA1c, HDL, and TC\HDL ratio risk factors played significant roles in creating the rules of 
the model. The predictive model showed that the participants with HbA1c > 6.45 and TC\HDL 
ratio > 5.5 are at risk of developing both diseases with probability 97.9%. In contrast, the 
participants with HbA1c > 6.45 and TC\HDL ratio < = 5.5 are more likely to gain only DM 
with probability of 84.5%. Participants with HbA1c <=5.45 and HDL > 1.45 are likely to fall 
under the healthy group with probability of 82.4%. The predictive model also showed 
participants with HbA1c <=5.45 and HDL < 1.45 are at risk of only CVD with probability 
(100%). 
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Figure 7-5. Exposes the constructed tree of the Proposed Model 
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Table 7-5 summarizes the rules and the diagnosis outcomes of the created tree of multi-
diseases. The created rules are straightforward to interpret, and thus physicians can use them 
to make proper decisions.  
Table 7-5. Induction rules of the Predictive Model. 
Terminal Node Rule Class 
6 If HbA1c is > 6.45 and TC\HDL ratio > 5.5 Then  Both 
5 If HbA1c is > 6.45 and TC\HDL ratio < = 5.5 Then DM 
4 If HbA1c <=5.45 and HDL > 1.45 Then  Healthy 
3 If HbA1c <=5.45 and HDL < 1.45 Then CVD 
 
The multi-diseases prediction outcomes of the validation sample based on the most 
common risk factors are presented in Table 7-6 (confusion matrix). As evident from confusion 
matrix, the performance of the predictive model is shown to be very good with a predictive 
accuracy of 94.09 %. Meanwhile, the sensitivity and the specificity of the predictive model 
were 93.5% and 95.8 % respectively. As presented in the confusion matrix, out of 244 there 
were 26 CVD participants incorrectly predicted. As for DM, the number of incorrect predicted 
participants was 12 out of 237. In the same context, out of 192 healthy participants the model 
incorrectly predicted eight participants. As for participants with both diseases there were two 
out of 139 participants are incorrectly predicted. The outsanding performance for this model  
Table 7-6. Confusion Matrix 
Predictive Class 
Actual Class 
A B C D 
218 12 0 14 A = CVD 
9 225 3 0 B = DM 
0 2 137 0 C = Both 
8 0 0 184 D = Healthy 
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7.5  Chapter summary 
A large number of predictive models have been developed to predict CVD and DM. Despite 
the outstanding performances of these models, they were proposed to predict only one disease 
at a time, either CVD or DM. This chapter discussed the development of a predictive model to 
predict CVD and DM simultaneously based on their common risk factors. The most common 
risk factors of these diseases were FH of the disease, gender, HbA1c, HDL and TC\HDL ratio, 
DBHR and LSBP. The predictive model showed good performance with accuracy of 94.08%, 
sensitivity of 93.5% and specificity of 95.8%. The outcomes of the present chapter have 
provided some pointers to assist doctors in diagnosing such diseases early in high-risk people. 
The predictive model can also be applied with various interrelated diseases. 
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Chapter 8: Conclusions and Future Directions 
This chapter provides an overall summary and discusses the methodologies of the developed 
models, the current study outcomes and the conclusion of this thesis. The chapter comprises 
two sections; in the first section, achievements of the study are presented. In the second section, 
some possible future research directions are suggested.  
8.1 The Achievements 
This study has succeeded in fulfilling many essential achievements that are directly related to 
real life. More specifically, several problems have been addressed in the field of health which 
is one of the most critical life fields. The present thesis focused mainly on one of the most 
significant diabetes complications known as cardiac autonomic neuropathy (CAN) disease. 
This disease affects many people worldwide.  
In this study, the following questions were answered. The first question was how 
angiotensin-converting enzyme (ACE) gene’s polymorphism is associated with the 
development of CAN’s disease. To answer this question, this research provided a cross-
sectional study that investigated the role of the gene in the development of CAN as presented 
in Chapter 3. The scope of the study covered the rural population in Australia. The role of the 
gene was examined using various statistical tests such as univariate statistical tests and logistic 
regression. Using logistic regression to assess the risk of factors is very common in medical 
research. This chapter note how the gene has a severe effect on developing the disease if the P 
value < 0.05. In this chapter, the risk of additional factors such as Ewing’s tests, blood tests 
and clinical data is assessed using multi sub-sets of factors. The outcomes of the investigation 
revealed that the angiotensin-converting enzyme (ACE) gene’s polymorphism is not a risk 
factor for developing the disease. The study confirmed that only Ewing’ tests among the 
included features have a significant effect on the development of CAN.  
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The second addressed question was about the risk of family history, Ewing tests, blood 
tests and demographic data of participants of the prevalence of diabetes. Diabetes is the leading 
cause of CAN. Many previous studies have assessed the risk of family history of the prevalence 
of diabetes. The risk of family history of diabetes however, varies among the different ethnic 
groups. The risk of Ewing’s tests of diabetes also has not been examined to the best knowledge 
of this researcher. To bridge this gap this study provided a cross sectional study in Chapter 4.  
The impacts of the covariates were tested using logistic regression and univariate 
statistical tests. All covariates were considered as risk factors when the P value < 0.05. The 
outcomes of this chapter demonstrated that family history and some of Ewing’s tests 
significantly contribute to the incidence of diabetes.  
The third question answered in this study was how heart rate variability (HRV) methods 
could participate in improving CAN’s disease prediction, particularly with incomplete set of 
Ewing’s tests. In this regard, chapter 5 of this thesis discussed the development of a predictive 
model to predict CAN using Ewing’s Tests combined with the essential HRV methods. These 
methods are simple to collocate, and they have shown their capability in diagnosing various 
diseases. The predictive model is proficient in automating the process of generating multi 
classifiers under one schema. It is straightforward to use in both Weka Simple CLI command 
line and the graphical user interface (GUI). Chapter 5 also domnstrated the most critical 
methods of HRV that could be used as alternative tests when one of the Ewing’s tests is 
unavailable. The higher obtained accuracy of the predictive model was 95%, and the ROC was 
0.978. 
  The fourth question addressed in the present study was how to predict the probability 
of CAN occurrence based on Ewing’s Tests. Despite the large number of proposed models for 
predicting CAN, the existing proposed models predicted the CAN category such as Normal, 
Early, Severe, Definitive and Atypical. In chapter 6 of this thesis, the focus of discussion was 
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the development of a useful predictive model to predict the probability of CAN occurrence. 
The predictive model uses the capabilities of logistic regression for this purpose. This model 
efficiently helps doctors and patients to predict the risk of developing CAN. It is very simple 
to use by both patients and doctors. The predictive model showed outstanding performance 
with high accuracy (87.34%). The sensitivity of the predictive model was also very good 
(87.12%), and the specificity was 87.5%. Type I Error, and Type II Error were 12.88% and 
12.5% respectively. 
The last question addressed in this study was how to predict diabetes mellitus (DM) and 
cardiovascular disease (CVD) simultaneously. These diseases are directly interrelated with 
CAN and controlling them significantly contributes to reducing the prevalence of the disease. 
Although many valuable studies have proposed to predict CVD and DM, however, they were 
only predicting one disease at a time, either CVD or DM. Chapter 7 of this thesis provided an 
answer to this question. In chapter 7 a predictive model to predict DM and CVD simultaneously 
using their common risk factors was elucidated. The predictive model is also able to predict 
these diseases individually. To build the model it was necessary to examine the risk factors for 
each disease, compare them and select the common risk factors. The achievements of the 
predictive model were very good with predictive accuracy of 94.09%, the sensitivity and 
specificity of the model were 93.5% and 95.8% respectively.  
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8.2 Limitations and Future Work 
This study introduced various models to predict cardiac autonomic neuropathy (CAN) disease 
and the most related diseases. This study has also provided two cross-sectional studies to 
investigate the effect of genes risk factors on the prevalence of CAN and DM. There is however 
still need to improve the existing work of the present study for it to be practicable in real life. 
For future work, there are possibilities to track many extensions as follows: 
 Assess the contribution of other genetic and non-genetic risk factors to the development 
of CAN. These factors would have different effects on CAN prevalence. The effect in 
some cases will be small, while in other cases it will be massive. The contribution of 
these risk factors to the development of CAN is also variant depending on gender and 
ethnicity. There should also be plans to investigate the effect of these factors on other 
populations. The number of participants was also small therefore; future studies should 
assess the effects of these factors on a larger sample size. Similarly, future research 
should apply the same procedure with cardiovascular disease (CVD) and Diabetes 
Mellitus (DM). This would be an improvement to the cross-sectional study as discussed 
in Chapters 3 and 4 of this thesis. . 
 Using Ewing’s battery tests in predicting CAN posed many challenges, which were not 
easily met by all participants in this study. These tests have been in use for three and a 
half decades and the availability of other tests should be exploited as alternatives to the 
traditional tests to overcome the obstacles encountered in Chapters 5 and 6 of this thesis. 
We would like also to exploit the capabilities of deep leaning algorithms  
 Diabetes Mellitus (DM) and cardiovascular disease (CVD) are the leading causes of 
CAN. Controlling these diseases will significantly help in reducing their complications 
such as CAN. Finding more common risk factors for these diseases would also facilitate 
the prediction of the diseases simultaneously. Providing an efficient predictive model 
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for these diseases would significantly decrease the prevalence of CAN. There is 
therefore a need to investigate more common risk factors that would improve the 
predictive accuracy of the predictive model described in Chapter 7.  
 Deep leaning algorithms have also shown an excellent performance with various real 
life problems, exploiting such algorithms could increase the accuracy of diagnosing 
CAN and the related diseases.   
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